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Abstract 
 
In the human organism more than 500 proteases have been described so far. Many of them 
are essential in the regulation of physiological processes, as inflammation, immune 
response, coagulation or growth. A dysregulation in protease activity corresponds to severe 
malfunctions and causes numerous pathophysiological diseases, as neurodegenerative 
disorders, cardiovascular diseases and cancer. When it comes to cancer, proteases play an 
important role in progression and metastasis. Some are secreted from the tumor and can be 
found in the extracellular matrix of the tumor microenvironment and also in the bloodstream.  
Functional protease profiling aims at discovering tumor associated protease activity in clinical 
specimens (serum, plasma and tissue), which could be used for diagnostic and prognostic 
purposes. Therefore, it is necessary to find substrates, which are specifically cleaved by 
cancer-associated proteases. Various approaches using antibody based antigen detection or 
MS-based techniques, are limited in the number of samples, which can be screened in 
parallel. To overcome these problems, peptide microarrays were used. Compared to Ronald 
Frank´s SPOT-synthesis, micro-particle solid phase peptide synthesis (mpSPPS) allows 
much higher peptide densities with up to 1000 different peptides per cm2, dependent on the 
layout. This PhD thesis dealt with the development of a high-throughput screening assay 
platform based on in-situ synthesized peptide microarrays. As first step a model system, 
using known proteases (trypsin, thrombin, proteinase k etc.), was developed. To check for 
general applicability of the PEGMA/MMA surface, on which the peptide synthesis takes 
place, the manufactured peptide microarrays, containing N-terminal antibody recognition 
sequences (FLAG- & HA-tags), were used without further chemical modification. After 
proteases incubation, the respective fluorescently labeled anti-FLAG- & anti-HA antibodies 
will only bind to peptides, bearing the intact tag-sequence, leading to a decrease in 
fluorescence intensity, where the enzymes were active. After demonstrating on-chip 
proteolysis, using indirect antibody labeling, the biotin-streptavidin system was introduced to 
minimize the peptide label to a smaller tag. This allowed greater sequence variability and 
avoided false positive cleavage, as when using a proteinogenic tag sequence. Together with 
the PEPperPRINT Company, a biotin toner was developed, to integrate this labeling reagent 
into the in-situ synthesis process, which turned out to be advantageous compared to in-
solution modification of the peptide content. To further overcome limitations on the part of the 
solid support, the polymer film was optimized, by introducing a new dextran surface. 
Preliminary experiments in lab-scale showed good proteolytic cleavages with model 
proteases and spotted peptides. The transfer to production scale however, showed the 
 requirement of optimization, regarding polymer composition and peptide density, which is an 
ongoing process. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Kurzfassung 
 
Bisher sind im menschlichen Organismus mehr als 500 Proteasen identifiziert worden. Viele 
von ihnen sind maßgeblich an der Regulation vieler physiologischer Prozesse, wie 
Inflammation, Immunabwehr, Gerinnung oder Wachstum beteiligt. Bei einer Fehlfunktion 
bzw. Dysregulation der Proteaseaktivität, kommt es in Folge zu gravierenden Störungen, die 
zu Entzündung, neurodegenerativen oder kardiovaskulären Krankheiten, bis hin zu Krebs 
führen können. Gerade bei Krebserkrankungen spielen Proteasen eine zentrale Rolle. Es ist 
bekannt, dass schon in frühen Stadien, tumor-assoziierte Proteasen sezerniert werden, die 
die Progression und Metastasierung des Primärtumors unterstützen und daher nicht nur im 
umliegenden Gewebe, sondern auch in der Blutbahn zu finden sind. Das funktionelle 
„Monitoring“ von Krebs-assoziierten Proteasen ist ein vielversprechender Ansatz die 
Proteaseaktivität in klinischem Probenmaterial (Serum, Plasma und Gewebe) zu 
untersuchen, um damit die Labordiagnostik von Tumorerkrankungen entscheidend zu 
verbessern. Die Analyse der tumor-assoziierten Proteaseaktivität ist durch die Inkubation mit 
geeigneten Substraten (Reporter Peptide) und dem Nachweis von spezifischen 
Spaltprodukten möglich. Derzeit sind Nachweissysteme auf Antigen-Antikörper Basis und 
massenspektrometrische Methoden weit verbreitet. Diese sind aber, aufgrund ihrer limitierten 
Zahl an parallel zu untersuchenden Proben, ungünstig. Um diesem Problem zu begegnen, 
wurden in der vorliegenden Dissertation s.g. Peptid-Mikroarrays genutzt. Im Gegensatz zu 
Ronald Frank´s SPOT-Technologie, können mittels der partikel-basierten 
Festphasenpeptidsynthese (mpSPPS) deutlich höhere Peptiddichten von bis zu 1000 
Peptiden per cm2, je nach Layout, realisiert werden. Es sollte im Folgenden eine Mikroarray-
basierte Screening-Plattform etabliert werden, um Analysen im Hochdurchsatzformat 
durchführen zu können. Im ersten Schritt wurde ein Modellsystem unter Benutzung 
bekannter Proteasen entwickelt (Trypsin, Thrombin, Proteinase K etc.). Um die generelle 
Funktionsfähigkeit der benutzten PEGMA/MMA funktionalisierten Mikroarrays für diese 
Anwendung zu überprüfen, wurden Träger mit N-terminalen antikörperspezifischen Tag-
Sequenzen (FLAG- & HA-tag) produziert. Ohne weitere chemische Modifikation, wurde eine 
Proteaseinkubation vorgenommen und anschließend zur Detektion eine Immunfärbung mit 
fluoreszenzmarkierten anti-FLAG und anti-HA Antikörpern durchgeführt. Diese binden nur 
vollständig intakte Tag-Sequenzen und zeigen daher eine Abnahme der 
Fluoreszenzintensität in den Peptidspots, die zuvor proteolytisch gespalten wurden. Nach 
erfolgreicher Demonstration der enzymatischen Aktivität, wurde das Biotin-Streptavidin 
System eingeführt, um die Tag-Sequenz zu verkleinern. Dies sollte zum einen die 
kombinatorische Vielfalt der Peptidsequenz vergrößern und zum anderen falsch-positive 
Spaltungen durch den Ersatz der proteinogenen Erkennungssequenz verhindern. In 
 Zusammenarbeit mit der PEPperPRINT GmbH, wurde ein Biotin-Toner entwickelt, der eine 
In-situ-Synthese des Markierungsbausteins ermöglicht, was eine deutliche Verbesserung der 
Peptidmarkierung, im Vergleich zu Kopplungen aus Lösung, zeigte. Des Weiteren wurden 
Optimierungen der Array-Oberfläche, durch die Einführung eines Dextranfilms, angestrebt. 
Erste Laborexperimente zeigten gute Ergebnisse der Proteolyse mit gespotteten Peptiden 
und Modell-Enzymen. Der Transfer in den Produktionszyklus zeigte schließlich 
Optimierungsbedarf was die Polymersynthese und auch die Peptiddichte angeht; zukünftige 
Arbeiten werden sich mit diesen Themen beschäftigen. 
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I. Introduction 
 
I.1. Peptides, Proteins & Enzymes 
 
In all living systems biomolecules are the major players. We mainly distinguish between four 
groups; lipids, polysaccharides, nucleic acids and proteins. Proteins consist of small building 
blocks, the amino acids, which are connected via amide bonds (peptide bond), to form 
peptides. There are 20 naturally occurring amino acids, out of which all resulting 
biomolecules are built. If the resulting polypeptide chain is longer than 50 residues, we 
usually speak of a protein. The exact amino acid sequence is called primary structure. Due to 
internal hydrogen bond formation, proteins show a special arrangement of their amino acid 
residues, which is referred to as secondary structure. Besides the α-helix and β-sheet 
conformation, the two regular forms of the secondary structure, there are a lot more like hair-
pin and coiled-coil structures. If we look at the arrangement of the entire polypeptide chain, 
we speak of the tertiary structure or protein folding, which is highly dependent on the 
surrounding conditions, for example in a cell. There, the polar residues will be exposed to the 
aqueous cytosol, whereas the nonpolar residues will tend to stick together in a hydrophobic-
like core. The term quaternary structure characterizes the conformation of several protein 
subunits, which can be stabilized by hydrogen bonds or disulfide bridges between the single 
subunits. Hemoglobin, the iron-binding protein complex of our red blood cells, is an example 
for a protein with four identical subunits and an additional prosthetic group to bind oxygen. 
Proteins in turn can be subdivided into five groups, the structural proteins as collagen and 
keratin are essential for the construction of our body. Storage proteins as the already 
mentioned hemoglobin and ferritin are responsible for housing critical elements, our cells 
need. Hormonal proteins act as chemical messengers; insulin, as common example, 
regulates the sugar level in the blood system. Another very important class of proteins is 
represented by the immunoglobulins, which act as antibodies, recognize pathogens and 
therefore support the immune system. Finally the perhaps most important group of proteins 
are the enzymes. They catalyze a great number of biochemical reactions occurring in a living 
organism. There are six classes of enzymes shown in table 1 on the next page. 
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Class Catalyzed chemical reaction Example 
Oxidoreductase 
Oxidation-Reduction in which oxygen and 
hydrogen are gained or lost 
Cytochrome oxidase, lactate 
dehydrogenase 
Transferase 
Transfer of functional groups, such as an 
amino, acetyl or phosphate group 
Acetate kinase, alanine 
deaminase 
Hydrolase Hydrolysis (addition of water) Lipase, sucrase 
Lyase 
Removal of groups of atoms without 
hydrolysis 
Oxalate decarboxylase, 
isocitrate lyase 
Isomerase 
Rearrangement of atoms within a 
molecule 
Glucose-phosphate 
isomerase,  alanine racemase 
Ligase Joining of two molecules Acetyl-CoA synthetase 
Table 1: Classes of enzymes. 
 
Although enzymes usually consist of hundreds of amino acids, only a few of them play a role 
in the actual catalytic process. This part of the protein is known as the active site. The overall 
structure of an enzyme determines the appearance of its active site. This fact allows the 
enzyme to address specifically its right substrate like a key fitting its lock. With their unique 
properties, enzymes play an important role in every living cell, from metabolic processes to 
signal transduction or DNA modification and many more. The systematic study of proteins 
concerning their structure and function in living organisms gained a great interest in the last 
20 years; since 1997 we call this field proteomics according to genomics, the study of the 
genome1. The entire set of proteins is therefore called proteome2.  
 
I.2. Proteases & Diseases, especially cancer  
 
Proteases, belonging to the group of hydrolases, catalyze the hydrolysis of amide bonds. 
Other than many reversible posttranslational modifications of proteins, like e.g. 
phosphorylation, proteolysis remains irreversible. Therefore proteolytic enzymes mediate 
processes that are themselves irreversible: coagulation, digestion, maturation of cytokines 
and prohormones, apoptosis and the breakdown of intracellular proteins. So proteolysis is a 
ubiquitous mechanism that regulates the function and fate of a protein3. The general 
mechanism, proteases are performing, is basically a nucleophilic attack on the carbonyl-
carbon of an amide bond. There are five classes of proteases, depending on the active site 
residue or ion that carries out catalysis, namely serine, threonine, cysteine, aspartic and 
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metallo proteases. As figure 1 illustrates, aspartic and metallo proteases immobilize and 
polarize a water molecule, so that the oxygen atom of water becomes the nucleophile. Serine 
and cysteine proteases use their –OH and –SH side chains directly as nucleophile. 
 
 
Figure 1: Schematic representation of the processes catalyzed by different classes of proteases:            
(a) serine protease; (b) cysteine protease; (c) aspartic protease; (d) metallo protease1 
 
The degradome database lists about 569 human proteases and homologs, whereas the 
serine and metallo proteases are the most densely populated classes4. The roles of 
proteases range from digestive functions, the removal of damaged proteins and protein 
maturation to the precise processing of regulatory proteins. The architectural design of 
proteases ranges from small catalytic units (~20 kDa) to protein degradation machines, like 
the proteasome. The structural organization of a protease induces its substrate specificity, 
right localization in the cell, kinetic properties and sensitivity to endogenous inhibitors5. 
Providing an important link between genetics and biochemistry, proteases act as key players, 
for example in signaling cascades like blood coagulation, inflammation, immunity, apoptosis, 
and many more6,7. Therefore it is obvious, that alterations in proteolytic systems underlie 
                                               
1 Erez, E., Fass, D., & Bibi, E. How intramembrane proteases bury hydrolytic reactions in the 
membrane. Nature 459, 371–378 (2009). 
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multiple pathological conditions such as cancer, neurodegenerative disorders, inflammatory 
and cardiovascular diseases5. So there has been an increasing interest in identification and 
structural characterization of proteases as potent pharmacological targets and also as 
diagnostic markers in the last decades8. Modern cancer research does not only focus on 
mutations in cancer cells but gained increasing interest in the extracellular matrix (ECM) of 
the tumor microenvironment, which has also a high impact in tumor progression9. MMP´s 
have been found to play a key role in regulating the ECM, as they can be found upregulated 
in almost every human cancer compared to normal tissue10. The relevance of proteases in 
the late stages of cancer has been known since a long time. Via degradation of the 
extracellular matrix, metastasis and tumor growth is supported dramatically. But also in early 
stages of a malignant tumor, proteases play an important role, for instance in modulating 
growth factors for the tumor progression11. Already today there are single cancer associated 
proteases with high diagnostic importance, like for example Kallikrein-related Peptidase 3, 
better known as prostate specific antigen (PSA), a serine protease12,13. Other proteases, like 
Urokinase Plasminogen Activator system (uPA/uPAR/PAI1), have shown to be of prognostic 
importance for the mamma carcinoma. uPA for example shows a correlation between the 
serum protease pattern and the respective primary tumor14,15. Also in colon cancer prognostic 
relevant protease profiles in primary cancer tissue could be identified relating to MMP´s and 
high activity/concentration of cathepsins in serum respectively16,17. Obviously secreted 
proteases from the tumor are not only present in its surrounding area but can be found also 
in the bloodstream18. Furthermore, cancer associated proteases are not only secreted by the 
primary tumor tissue but also from the surrounding connective tissue and also infiltrated 
leukocytes19,20. Today individual highly expressed proteases for numerous tumor entities in 
tissue, serum and plasma samples have been described, which are relevant for prognosis21. 
 
I.3. Protease profiling 
 
The methods for identifying proteases in clinical specimen of cancer patients are nowadays 
based on antigen detection. However there is frequently no differentiation between 
zymogenes and active proteases possible22. This differentiation is mandatory because in 
most cases proteases are regulated via activation of zymogenes rather than in the gene 
expression level23. Although activity measurements are advantageous over antigen 
detection, only single substrates have been identified so far24,25. The detection of MMP-2 
activity in serum samples for example can be monitored down to a concentration of 1ng/ml, 
by using the specific reporter peptide with the sequence IPVSLRSG26. When measuring 
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different protease activities in serum specimen in parallel in a multiplex-analysis, the 
sensitivity and specificity of protease profiling can be increased26. The major challenge is to 
find suitable reporter peptides, which are specifically cleaved by cancer associated protease. 
If the protease is available in high purified or recombinant form, specific substrates can be 
screened by using an in-solution or surface-based library of fluorescent labeled 
peptides27,28,29. Another problem is the limitation of the complexity of conventional peptide 
libraries from several hundreds to thousand substrates, due to the high costs of synthesizing 
fluorescently labeled peptides. This makes the identification of a sufficient number of reporter 
peptides difficult. However, due to the heterogeneity of the protease profiles during tumor 
progression and in different tumor entities, a sensitive and specific multiplex-analysis is 
obligatory to detect different protease activities simultaneously25. The utilizability of such a 
multiplex-analysis has been already demonstrated in model systems using caspases and cell 
lysates30. The transfer of functional protease profiling for clinical specimen like serum, tissue 
and plasma remains to be investigated. 
 
I.4. Peptide arrays 
 
In the last two decades, new technologies based on microarrays found their way into the 
labs, improving many biological and clinical diagnostic approaches. Today the demand of 
investigating complex systems in a high-throughput format increases. In genomic research, 
for instance, this lead to the development of DNA-microarrays, which are routinely used to 
screen thousands of molecules and their specific interactions with a sample in parallel. 
Typically those microarrays are synthesized by either lithographic, electrolytic or 
electrophoretic techniques31,32,33. Photolithographic methods are capable of producing highly 
ordered arrays with more than 250,000 oligonucleotides per cm2[34]. Using randomly orders 
bead arrays, even higher densities over one million features per cm2 are possible and are 
used for whole-genome genotyping35,36,35,37. However, most important interactions in 
vertebrates are ongoing on the proteome level, which results in a much higher complexity 
compared to the genome. The development of high-throughput arrays on a protein level is 
therefore much more challenging, due to 20 building blocks, the proteinogenic amino acids, 
of which all proteins are consisting of, compared to the four nucleotides in our DNA. In 2000 
MacBeath et al. demonstrated the first protein array on a support37,38. 
The synthesis of peptide arrays, in contrast, is an easier task. Although the detection of 
interactions, which need extended protein regions or complex folding, is not possible, peptide 
arrays provide plenty of possible applications in proteomics. For example, many protein 
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interactions are mediated by peptide recognition modules, as SH2, SH3 etc. Those are 
peptide sequences, which are embedded in protein binding pockets39. Other approaches can 
be binding studies for antibody characterization (epitope mapping), biomarker screening or 
enzyme profiling. 
This PhD thesis dealt with the development of an high-throughput assay system to measure 
enzyme activity in various samples, in order to identify new reporter peptides, specifically 
cleaved by cancer associated proteases. 
 
I.5. High-density peptide arrays 
 
In order to assemble as many peptides on a microarray as possible, early approaches 
focused on pre-synthesizing peptide libraries and spot them on a solid support, preferably on 
glass slides. Figure 2 shows the schematic workflow of the combinatorial synthesis/ SPOT-
synthesis.  
 
Figure 2: Schematic overview SPOT-synthesis. (a) A spotter positions the four activated bases for 
oligonucleotide synthesis or the 20 different C-terminally activated amino acid derivatives for peptide synthesis, all 
contained within liquid droplets, to defined areas on a solid support. (b) They are then coupled to this support in 
parallel. A cycle of synthesis is completed when (c) excess monomers are washed away and (d) the transient 
protection group is removed. Repetitive coupling cycles generate an array of oligonucleotides or peptides, the 
sequences and positions of which are known.2 
However, the disadvantages of this method are the high cost and the technical limitations by 
using the SPOT-technique, resulting in maximal peptide densities of around 25 spots per 
cm2[40]. Obviously small droplet volumes are difficult to handle, regarding evaporization or 
                                               
2 Breitling, F., Nesterov, A., Stadler, V., Felgenhauer, T. & Bischoff, F. R. High-density peptide arrays. 
Mol. Biosyst. 5, 224–234 (2009). 
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their spreading over the array. Ronald Frank invented peptide arrays, where the peptides are 
directly synthesized spot on spot on a cellulose support. This made the synthesis cheaper 
and even large numbers of small proteins available41,42. To overcome those limitations a 
variation of the SPOT-synthesis, the so called SC2 method was developed43. Here, individual 
peptides are synthesized on a large cellulose area, afterwards deprotected by using TFA, 
which breaks down the cellulose support and small peptide-cellulose conjugates are formed. 
These collected conjugates can be spotted in high-density in a second step onto another 
solid support, like for example glass slides. This procedure allows for highly reproducible 
production of multiple densely spaced peptide array replicas40. Although patented already in 
1994, high-density peptide arrays, manufactured by using an ink-jet printer, as it is done e.g. 
through Agilent´s SurePrint Technology for oligonucleotide arrays, have not yet been 
reported44,45. The solvents needed in peptide chemistry are thought to be problematic when it 
comes to ink-jet printing, due to their viscosity, which might be incompatible with this 
technique. 
Transferring lithographic methods, originally invented to produce computer chips, to the 
microarray field, allowed for the first time the production of truly high-density arrays, 
revolutionizing first the world of genomics31,46. Figure 3 shows the schematic overview of this 
technique. 
 
Figure 3: Lithographic synthesis. (a) A pattern of light defines first areas on a 2D solid support. (b) There, 
through irradiation, the transient protection group at the tip of the growing oligomer chain is removed. (c) Next, the 
whole support is uniformly covered with one of the 20 different C-terminally activated amino acid derivatives. 
These are coupled only to those structures deprotected by the previous lithographic step. (d) Excess monomers 
are washed away. These steps are repeated four times with the four different nucleotides or 20 times with the 20 
different amino acids to add one layer during the synthesis of oligonucleotides or peptides, respectively. 
Repetitive coupling cycles generate an array of oligomers.3 
 
                                               
3 Breitling, F., Nesterov, A., Stadler, V., Felgenhauer, T. & Bischoff, F. R. High-density peptide arrays. 
Mol. Biosyst. 5, 224–234 (2009). 
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Fodor et al. showed, for the first time, that also peptide arrays can be manufactured by using 
lithographic methods31. One drawback is the necessity of a large number of coupling cycles. 
To generate a 10 mere peptide array, for instance, 20x10 cycles are needed, compared to 
4x10 for a 10 mere oligonucleotide array. The difficulty is that the more coupling cycles that 
are performed, the more side-reactions can occur. Another disadvantage was the need of 
photolabile protections groups, resulting in poor coupling yields. For further information about 
other lithographic approaches and improvements, reference is made to the literature32,33,47,48. 
The former group Chip-based Peptide Libraries at the DKFZ developed a method for 
combinatorial synthesis of peptide arrays by using solid amino acid particles. These 
triboelectrical charged particles can then be positioned on a 2D-support using electrical fields 
by either a laser printer or on a computer chip. Up to 40,000 peptides per cm2 are possible 
with this approach29,49. Figure 4 illustrates the schematic workflow of this particle-based 
synthesis with a laser printer. 
 
Figure 4: Positioning amino acid particles with a laser printer. (a) A laser printer positions Fmoc-amino acid-
OPfp esters embedded within solid toner particles onto a solid support derivatised with free amino groups. (b) The 
particles are melted after transfer. As a result, oily reaction spheres are formed by surface tension. This 
procedure frees previously immobilized chemically activated amino acid derivatives and allows them to diffuse. At 
the same time, very small reaction spheres are separated from one other, allowing for elongation of growing 
peptides in parallel and at high density. A cycle of synthesis is complete when (c) excess monomers are washed 
away and (d) the Fmoc protection group is removed. Repetitive coupling cycles generate a peptide array with one 
coupling cycle per layer. Peptide length is determined by the number of coupling cycles.4 
This method uses standard Fmoc-chemistry together with a solid solvent (at RT), which 
allows the embedding of activated (C-terminal Opfp-ester activation) amino acids within 
these particles50. The big advantages are the great stability of the activated amino acid 
compounds within the matrix of the particles and the possibility to consecutively position 
different particles next to each other onto the solid support before melting and induction of 
                                               
4 Breitling, F., Nesterov, A., Stadler, V., Felgenhauer, T. & Bischoff, F. R. High-density peptide arrays. 
Mol. Biosyst. 5, 224–234 (2009). 
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coupling49. The melting step gives highly viscous reaction spheres, which allow the reaction 
to take place restricted to its desired spot, avoiding cross-contamination. Finally this method, 
commercialized in the PEPperPRINT Company (Heidelberg, Germany), allows building up 
peptide arrays with up to 280,000 individual peptides. For further information about the 
theoretical background and the commercialized products, reference is made to the literature 
and the webpage of the PEPperPRINT Company51. 
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II. Project Aims 
 
II.1. General Idea 
 
For solid tumors, numerous pathophysiological relevant proteases are described, which 
promote the progression of melanoma, including several metallo-, serine- and cysteine 
proteases, as well as cathepsines. For some tumor entities, proteases as 
diagnostic/prognostic markers have already been identified. Normally the detection of cancer 
associated proteases from clinical serum-, tissue- or plasma samples uses immunological 
approaches. Due to the absence of specific and sensitive substrates, activity measurements 
are not widespread. Therefore, cancer specific marker peptides have to be identified by 
using high-density peptide microarrays, manufactured by the PEPperPRINT Company, in 
order to screen large peptide libraries in parallel. Functional protease profiling should be 
performed with clinical samples from different tumors, as colon-, mamma-, pancreatic-, 
prostate- and lung cancer. Selected substrates, which are differential processed compared to 
a healthy control cohort, will be then further optimized. Finally a peptide microarray, 
containing all potential substrates, will be constructed for validation with various biobanks. 
 
II.2. State-of-the-art 
 
Since many years Findeisen et al. (Institute for clinical chemistry, UMM, Mannheim) deal with 
the analysis of clinical serum and plasma samples by using mass spectrometry (Proteomic 
Profiling)52. Especially low molecular weight peptides are generated due to proteolytic 
cleavage out of serum proteins8,53. Because of the high proteolytic activity in serum 
specimen, there is also a high pre-analytical variability, which makes standardization difficult. 
Therefore, MS-based profiling is highly limited for diagnostic applications. Even when using 
standardized conditions, the analysis will not lead to the identification of cancer-associated 
proteases, rather than cleavage products and fragments of high-abundant serum 
proteins54,55,56. The abundance discrepancies of serum proteins are in the range of 10 
logarithmic levels but the dynamic measurement range of mass spectrometry is only 2-3 
levels. To display low-abundant proteins, excessive fractionizing is mandatory, which cannot 
be done in high-throughput format; also the reproducibility is not ensured57,58. To overcome 
these problems, an excess of exogenous reporter peptides was used, in order to replace the 
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endogenous serum proteins, so that the reporter peptides will be preferably cleaved by 
cancer-associated proteases. The resulting profiles of the different processed reporter 
peptides represent the tumor-associated protease activity in the individual serum samples 
and are the basis for further clinical classification59,60. Protease profiling using reporter 
peptides can be standardized and is very sensitive, due to accumulation of cleavage 
products and therefore also of the signal61. Figure 5 shows the exemplary construction of a 
reporter peptide for the cancer-associated protease Cancer Procoagulant (CP) (EC 
3.4.22.26), which is secreted by several solid tumor entities and can be found in high activity 
in serum samples of cancer patients62. 
 
Figure 5: Example for the construction of a reporter peptide for MS-based protease profiling. From 
database research a peptide sequence is identified and several structural elements (affinity-tags, linker, and stop-
elements) are added, which are relevant for sensitive detection via MS. After addition of the reporter peptide to 
the serum sample, the cleavage of the reporter peptide by the endoproteinase CP at its specific cleavage site (red 
lightning) begins. The resulting fragment is then cleaved by exoproteases (green lightnings) to the non-cleavable 
ancor-peptide with the mass 1055 [M+H+]. 2Abu: 2-amino-butyric acid; Ahx: amino-hexanoic acid; t: d-threonine.5 
So far the number of relevant substrates, which could be identified via MS, is limited, due to 
their low specificity in serum samples. Also the substrate specificity is a major problem in the 
present used assays63. Furthermore the number of peptides, which can be screened in 
parallel, is highly limited, due to the complexity of the MS data, with the increasing number of 
fragments. 
 
 
 
                                               
5 Findeisen, P.; Yepes, D. (2013) 
2: unspez. Exoproteasen
Ahx-HHHHHHtAnker-Peptid (stabil): m/z 1055
---PDSIT-WKPYDAAD-LDPTE---FX, P00742
DAAD-Ahx-HHHHHHt
1: CP Cancer Procoagulant
Biotin-2Abu-Ahx-WKPYDAAD-Ahx-HHHHHHtReporter-Peptid
In vivo
In vitro
CP
12 
 
II.3. Work Plan 
 
In order to find new substrates, which are specific for cancer-associated protease activity, a 
high-throughput assay system, based on high-density peptide microarrays, has to be 
developed. For this purpose random peptide libraries, as well as sequences identified via 
database research, together with positive and negative controls will be used, to design a 
screening chip. The microarray manufacturing and peptide synthesis was conducted to the 
PEPperPRINT Company. Their innovative technology using a laser-printing approach to 
produce high-density peptide microarrays is advantageous regarding complexity and cost 
effectiveness.  To detect and monitor proteolytic activity in a sample of interest, the peptides 
have to be modified with a label, which can be read out during and after enzyme incubation. 
The most convenient way is a fluorescent labeling of the peptides, which can be easily read-
out with an appropriate scanner. Figure 6 shows the attachment of a fluorescent dye to the 
free N-terminus of the peptides. After proteolytic cleavage, the fragment, which bears the 
labeling reagent will be washed away, which leads to a reduction or even deletion in 
fluorescence intensity for this individual spot. 
 
Figure 6: Schematic workflow of fluorescence labeling and proteolysis. 
End-point measurements can be easily performed by using common UV/Vis- or near-infrared 
scanners, depending on the emission wavelength of the used dye. On-demand kinetics will 
be measured by the collaboration partners at IMTEK (University of Freiburg) in a microfluidic 
device. 
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First a model system will be developed, testing different fluorescent reagents, regarding 
compatibility with the synthesis process, including subsequent deprotection of the peptides. 
Further it will be focused on labeling efficiency and signal-to-noise ratio. In the next step 
proteolysis will be performed, using known enzymes, to analyze substrate specificity and 
sensitivity, as well as surface applicability. After validating the system, clinical specimen will 
be tested.  
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III. Results & Discussion 
 
In this thesis the development of a high-throughput array-based enzymatic assay-system 
was performed, using high-density peptide microarrays (PEPperChipTM) from PEPperPRINT© 
GmbH. In the first part of this chapter, different labeling approaches are discussed, in order 
to measure the enzymatic activity in a sample of interest on the array. Therefore the in-situ 
synthesized microarrays were directly used as delivered. 
In the second part, optimizations of the surface coating and alternative polymers are 
discussed in terms of biocompatibility, applicability and sensitivity of the assay system. It has 
to be mentioned, that the standard synthesis surfaces for the laser printer-based peptide 
array synthesis have a format of 22 x 21 cm2. Therefore, only reaction conditions, which 
could easily be up-scaled to this format, were of interest. This excludes either sensitive 
materials, which for example have to be held under inert gas atmosphere or have no 
chemical robustness or very cost-intensive reactants. 
 
III.1. Labeling of in-situ synthesized peptide microarrays (PEPperChipTM) 
III.1.1. Direct labeling using fluorescent dyes 
 
In order to develop an on-chip proteolytic assay system based on peptide microarrays, the 
most convenient method is to modify the peptides with a specific label, which can be read out 
in an on-demand or end-point measurement. The most convenient method is using 
fluorescent dyes, which are commercially available in various forms, depending on the 
coupling chemistry used and the wavelength of interest. This chapter provides an overview of 
the most common coupling chemistries used in peptide chemistry, together with their assets 
and drawbacks for the targeted assay platform. 
 
III.1.1.1. Amino-chemistry 
 
Because the peptides synthesized on the microarrays are oriented from C- to N-terminus, the 
easiest way to label them is via the N-terminal amino group, which has to be deprotected 
with a 50 % (v/v) piperidine / DMF solution, prior to further use. There are mainly two reaction 
strategies; one is to use standard Merrifield chemistry, by incubating the peptide array with a 
slightly basic mixture of a fluorescent dye with a free carboxylic group and an activation 
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reagent. Usually compounds of the carbodiimide family, like DCC, are used to form an O-
acylisourea intermediate. Newer developments use triazoles and uronium-based coupling 
reagents like HOBt and HBTU to avoid racemization64. Figure 7 illustrates the mechanistic 
details. 
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Figure 7: Coupling of a free carboxyl group to an amino group using standard Merrifield chemistry with 
HBTU and HOBt as activation reagents 
 
In the first step the carboxyl group is deprotonated by a base. The resulting carboxylic anion 
can then attack the activation reagent HBTU, to form an O-acylisourea intermediate, which is 
replaced by HOBt, releasing N,N´-tetramethylurea. The OBt--residue as good leaving group 
can finally be attacked by the amino group of the immobilized peptides, to form the labeled 
adduct. Another strategy is to use pre-activated compounds. A huge variety is commercially 
available, for example OPfp-esters, for usage in organic solvents or NHS- and sulfo-NHS-
esters, which can be used in aqueous media and are therefore advantageous for 
biochemical reactions. Figure 8 shows the reaction schematically. The reaction mechanism 
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is a simple nucleophilic substitution (SN2-reaction), with the activated ester as a good leaving 
group. 
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Figure 8: Mechanism of an NHS-ester activated reactant coupling to a free amino group 
 
Prior to any enzyme incubation, the peptide side-chain protecting groups have to be removed 
by using a 95 % TFA solution. Because of their acid stability, fluorescent dyes of the 
Tetramethylrhodamine (TAMRA) family were used, namely the free acid for Merrifield 
coupling and its NHS-ester homologue for reactions in aqueous buffer. The two mentioned 
reaction chemistries were studied, following standard protocols.  
 
 
 
 
Figure 9 shows the two amino mediated labeling trials. The signal-to-noise ratio for the 
HBTU/HOBt coupling is with a value of 2.26 slightly better than TAMRA-NHS with 1.75 
respectively. The variances in labeling efficiency could be attributed to electrostatic 
interactions between the charged dye molecules and the peptide backbones, if compared 
with the biotin labeling in chapter III.1.2.3. Highly fluorescent peptide spots tend to have a 
balanced number of positive and negative charged amino acid residues or a large number of 
nonpolar rests. Also N-terminal located glycine and serine rests seem to have a positive 
impact on the fluorescent intensity. On the other hand, peptide sequences containing 
aromatic amino acids, as tryptophan, phenylalanine tyrosine or histidine show dark spots, 
which can be explained due to intramolecular quenching65. A high number of acidic residues 
Figure 9: Peptide array N-terminal labeled with 1mM TAMRA-Lys-COOH, using HBTU/HOBt as activation 
reagents (left) and 0.02mM TAMRA-NHS (right). Read out was performed on the Genepix scanner (PMT400). 
17 
 
resulted also in a low fluorescence intensity. However, no general trend can be observed 
here. The following protease incubation though, showed no cleavage of any peptides 
compared to the buffer control (fluorescence scan not shown). A sterical hindrance of the 
proteases due to the attached dye molecule can be excluded. In the dissertation of Yepes, it 
was shown that TAMRA-labeled spotted peptides are successfully cleaved on the standard 
PEGMA/MMA surfaces66. Another possibility could be cross-reactivity of the activated 
reagents with hydroxyl groups in the polymer, which maybe remained uncapped during the 
synthesis process, especially in deeper layers. Therefore, thiol chemistry, as more specific 
reaction chemistry, was tested below.  
 
III.1.1.2. Labeling via maleimide activated fluorescent dyes (Thiol chemistry) 
 
In order to avoid any side reactions, possibly occurring, when using amino chemistry, 
labeling via maleimide activated dyes was tested. Maleimide esters selectively couple to 
thiol-residues in a Michael addition (Figure 10). Therefore, the peptide content was adapted 
with an N-terminal cysteine in the synthesis process. Another advantage over the amino 
labeling is that this reaction pathway allows free choice of a fluorescent dye, because the 
labeling step can be performed after side-chain deprotection. This represents a crucial step 
because many fluorescent molecules are labile against strong acidic or basic conditions. 
Maleimide groups will only react with thiol groups, when working under neutral or slightly 
acidic pH, so the amine remains protonated and is therefore a bad nucleophile, compared to 
the –SH group67. Therefore no cross reactivity should occur.  
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Figure 10: Mechanism of a maleimide activated compound coupling to a thiol residue (Michael addition). 
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The free electron pair of the sulfur atom can undergo a nucleophilic addition to the double 
bond of the maleimide ring. The resulting carbanion is stabilized by the –M effect from the 
keto groups and can finally react with a proton in solution to form the saturated product. For 
the maleimide based peptide labeling three fluorescent dyes, commonly used in our lab, 
were tested in different concentrations. Prior to dye incubation, the peptides were fully 
deprotected, following standard protocols. Like the NHS couplings, the reactions can be 
performed in aqueous media. As depicted in Figure 11, much less reagent for labeling is 
necessary to yield similar fluorescence intensities, compared to the amino coupling, about 
1500 fold for TAMRA and 3500 fold for the infrared dyes respectively. The overall labeling 
homogeneity of the infrared dyes is lower than for TAMRA. Besides the possible quenching 
effects, mentioned before, steric hindrance caused by their around two fold higher molecular 
weight, could also contribute. The signal-to-noise ratio on the other hand is with 6.06 for 
Atto680-Mal and 13.71 for Dylight800-Mal better than for TAMRA-Mal with 3.27, which 
indicates again cross-reactivity of dye molecules. Because of the, in theory, high specificity of 
the thiol-maleimide reaction, another explanation could be non-specific adsorption to the 
surface polymer and/or peptide backbones, due to hydrophobic and/or electrostatic 
interactions. Furthermore, no proteolytic cleavage of the peptide content could be observed 
either. To further optimize the labeling specificity and to check, if it is a matter of non-specific 
adsorption, alternative reaction chemistry was introduced below.  
 
III.1.1.3. Click chemistry 
 
In order to avoid non-specific reactions of the labeling reagent with any functional group, 
which could be left after production, another common coupling strategy, the so called click 
chemistry was tested. This labeling approach is based on a biorthogonal reaction chemistry 
between both an alkyne or phosphine residue and an azido group under mild aqueous, 
catalyst-free conditions, without possible side reactions because of the limited number of 
Figure 11: Comparison of maleimide dyes, I.a) 0.3µM Atto680-Mal; I.b) 0.3µM Dylight800-Mal and I.c) 0.7µM 
TAMRA-Mal. Read out was performed on the Odyssey scanner for near-infrared dyes (Atto, intensity 4 and 
Dylight, intensity 7) and GenePix scanner for TAMRA (PMT400). 
 
I.a I.b I.c 
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reaction partners of the azido group68. For the labeling, the peptide microarrays were N-
terminally modified with β-azido-alanine out of solution, following standard Merrifield 
chemistry and the subsequent orthogonal deprotection steps. Labeling was performed with a 
Dylight550-phosphine dye via Staudinger ligation, following the manufacturers’ protocols.  
 
 
Figure 12: Mechanistic details of the Staudinger ligation using a phosphine modified fluorescent dye and 
an azido residue.  
As depicted in Figure 12, the first reaction step of the phosphine coupling is an electrophilic 
addition of the free electron pair from the phosphorus to the electropositive nitrogen of the 
azido residue, followed by an aza-ylide transition state. The release of dinitrogen leads to an 
intramolecular rearrangement, forming the final amide bond. Figure 13 shows the 
fluorescence scan after labeling with Dylight550-phosphine. The need to increase the PMT 
value up to 600 (scan intensity), points out the low coupling efficiency, although the labeling 
reagents were used in excess. Also the suboptimal signal-to-noise ratio 1.5< is a major 
disadvantage and results partly from the auto-fluorescence of the glass. However this result 
indicates a non-specific binding of the dye to the surface polymer. However it has to be taken 
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into account that in-solution coupling of β-azido-alanine could also lead to cross reactions 
with functional groups in the polymer film, as assumed for the reagents coupled via Merrifield 
chemistry (see III.1.1.1.). This makes a distinction between cross-reactivity and non-specific 
binding to the polymer difficult. 
 
 
In order to test whether it is a matter of nonspecific physisorption of the fluorescent dye to the 
surface polymer, or covalent binding to functional groups, which have not been capped 
during the synthesis process, a peptide array was incubated with an azido functionalized 
TAMRA. Because the azido group cannot react with any functional group available on the 
surface, which might occur due to the synthesis process, no fluorescence should be 
detected. 
 
Figure 14: Fluorescence scan of a peptide array incubated with 10µM TAMRA-PEG(3)-N3. Due to the 
orthogonal reaction chemistry no labeling should occur; Read out was performed on the GenePix scanner (PMT 
500).  
As Figure 14 illustrates, a fully labeled peptide pattern can be seen, which proofs the non-
specific binding of the fluorescent dye to the PEGMA/MMA film, which presumably can be 
attributed to hydrophobic and/or electrostatic interactions. Experiments using TAMRA-COOH 
without any activation reagents showed similar results. Especially the high proportion 
Figure 13: Peptide array N-terminally modified with 10mM Fmoc-β-azido-alanine and labeled with 10µM 
Dylight550-phosphine. The PMT value was increased due to the poor coupling yield; high background 
fluorescence hampers the analysis. Read out was performed on the GenePix scanner (PMT 600). 
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adsorbing to the peptide spots could be explained with the remains of silica and other matrix 
components of the micro particles, deposited onto the solid support during peptide synthesis. 
 
III.1.1.4. Labeling via fluorescein arsenical hairpin binder ethane dithiol 
 
Over the past few years the green fluorescent protein (GFP) or similar genetically encoded 
proteins, have become a very popular method to label proteins69. Unfortunately such a 
proteinogenic label cannot be used when working with an enzymatic assay system, because 
the label itself would be digested. In order to solve the problems occurring with the large 
protein sizes, metal chelating agents were designed, binding specifically to a small peptide 
motif. The fluorescein arsenical hairpin binder represents such a reactant, binding selectively 
to a tetra cysteine motif CCXXCC as illustrated in Figure 15, where X stands for a various 
amino acid70. This small binding site can easily be implemented into the peptide sequences, 
synthesized on the peptide microarrays and can therefore be used for a specific labeling of 
the peptide content prior to enzyme incubation. Interestingly, when not bound to its binding 
motif, the arsenic compound remains non fluorescent, so even if it adsorbs nonspecifically to 
the polymer surface, no fluorescent signal should be detected. Figure 16 shows the labeling 
of a peptide content, where each peptide bears a tetra cysteine motif at various locations 
within the sequence, except the first row and the left column, which represent a FLAG/HA-
epitope control frame. For the first test the same concentration of labeling compound was 
used, as found in commercially available labeling kits, for example from life technologies. 
Due to the high PMT value and long incubation time needed, an excess of FlAsH-EDT2 was 
finally used together with DTT as reducing agent to avoid the formation of disulfide bridges 
between the cysteine residues, which would inhibit the complexation. This resulted in higher 
fluorescence intensities with signal-to-noise ratios of 1.26 and 1.27 respectively, which is 
possibly caused by auto-fluorescence of the glass itself. However the resulting pattern shows 
a lack in specificity of the arsenic compound. In Table 2 exemplary peptide sequences are 
pointed out. 
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Figure 12: Synthesis of FlAsH-EDT2 and proposed structure of its complex with a α-helical tetra cysteine 
containing peptide/protein domain 6 
 
 
 
 
 
 
 
 
Sequence Average fluorescence intensity [%] 
H2N-YPYDVBDYAGSGSGS (HA-Tag) 44 
H2N-DYBDDDDBGSGSGSG (FLAG-Tag) 50 
H2N-QSYDSBDYSDCCXXCC (HA-rel-Tag) 67 
H2N-CCXXCCDYBDDDDBGS 28 
H2N-CCXXCCQSYDSBDYGS 4 
H2N-CCXXCCYPYDVBDYAG 0 
Table 2: Exemplary peptide sequences labeled with FlAsH-EDT2 with their corresponding average 
intensity values. B stands for the amino acids K and R; X stands for a various amino acid. 
The highest fluorescence intensities were achieved with a combined sequence of HA-rel-Tag 
(HA - Human serum albumin) attached to the C-terminal tetra cysteine motif. The FLAG-Tag 
sequence also yielded high intensities both combined with other sequences or as stand-
                                               
6 Griffin, B. a, Adams, S. R. & Tsien, R. Y. Specific covalent labeling of recombinant protein molecules 
inside live cells. Science 281, 269–272 (1998). 
Figure 13: Peptide array labeled with 0.2mM FlAsH-EDT2 overnight (left) and 7.5mM FlAsH-EDT2 + 0.1M 
DTT as reducing agent over 2h (right). Readout was performed on the GenePix scanner (PMT600). 
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alone motif, whereas the HA-Tag shows fluorescence only when bound to other domains 
than the tetra cysteine sequence. If taken N-terminally, the tetra cysteine motif showed only 
low intensities; the best results were yielded in combination with the FLAG-Tag. For all tested 
sequences replacing amino acid B with an alanine lead to no fluorescence, which indicates 
the necessity of the amino group for complexing the arsenic atoms. It seems that aspartic 
acid, tyrosine and also amino residues are able to complex the arsenic centers of the dye 
when they take the right orientation to function as π-donor. For binding the tetra cysteine 
motif, the right location in the peptide sequence as well as the surrounding domains seem to 
be critical to form a proper α-helical orientation. For the desired assay system, the label 
needs to be attached N-terminal, so that an enzymatic cleavage of the subjacent peptide 
sequence can be assured. Preliminary experiments showed that the arsenic compound lacks 
in binding its tag specifically when it is located N-terminally. Due to this incompatibility, 
FlAsH-EDT2 was not pursued further.   
 
III.1.1.5. Short summary and conclusion 
 
In the first part of this chapter it has been shown that labeling via NHS-ester activated 
fluorescent dyes, as well as standard Merrifield chemistry, lead to similar results, regarding 
fluorescence intensity and signal-to-noise-ratio. However the NHS-ester turned out to be 
advantageous, due to the lower amount of reagent needed and the possibility to use 
aqueous buffer conditions instead of organic solvents. Because of the subsequent 
deprotection step with a TFA solution, acid stable fluorescent dyes of the 
tetramethylrhodamine family (TAMRA) were chosen. The peptide sequence composition in 
each spot turned out to highly influence the resulting fluorescence intensity, in terms of 
polarity, charge and quenching. However, a successful proteolysis after labeling could not be 
achieved. Sterical issues were excluded, due to the positive cleavage of TAMRA-modified 
peptides in spotting experiments of Yepes. The possible cross-reactivity with functional 
groups, which could have remained uncapped during the synthesis process, especially in 
deeper polymer layers, lead to the introduction of a more specific alternative labeling 
strategy. Reactions via maleimide activated compounds and cysteine residues are highly 
specific, as long as the reaction parameters, especially the pH value, are controlled. Another 
advantage is the possibility to use not only acid stable, but the whole spread of fluorescent 
dyes available because the side chain deprotection can be performed before labeling and not 
afterwards. However, labeling via maleimide activated fluorescent dyes showed no 
significant increase in specificity. To test if it is a matter of cross-reactivity with remaining 
functional groups in the polymer film or rather a problem of non-specific adsorption, click 
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chemistry was used. Incubation of unmodified peptide content with an azido-TAMRA and 
also its free acid without activation reagents, revealed non-specific binding of the dye to the 
polymer surface and especially to the peptide spots. In the dissertation of Münster it was 
found that due to the melting process of the micro-particles, the silica based matrix forms a 
porous landscape on top of the polymer film. Even with stringent washing there might remain 
rests of silica or other matrix components, causing unwanted side effects, due to for example 
hydrophobic interactions, leading to the observed unspecific binding of labeling molecules.71 
This effect was mainly observed when performing reactions from solution. Further it seems 
that in-solution reactions allow the diffusion of reactants deep into the polymer film, whereas 
using the in-situ method only a local restricted penetration because of the gel-like pillow, 
which is formed while melting the micro-particles, is achieved. Unfortunately it is not possible 
to implement fluorescent dyes into the micro-particle based synthesis, due to technical 
issues. To overcome this problem a fluorescein based arsenic compound, which shows only 
fluorescence, when complexed with its binding motif, was tested. However transferring this 
method to peptide microarrays showed a lack in specificity, most likely due to the false 
orientation of the peptides relative to the arsenic centers of the fluorescent dye. Checking for 
proteolysis after labeling with a fluorescent dye (no matter which labeling chemistry was used 
before), using standard enzymes, as proteinase k and trypsin, showed no decrease in signal 
intensity at all. It can be assumed, that the non-specific interactions of dye molecules with the 
polymer surface and remnants of the micro-particle matrix within the peptide spots, present 
an overlap, so that the actual decrease in fluorescence intensity due to proteolysis cannot be 
detected. In order to check if on-chip proteolysis is working in general with the PEPperChipTM 
system, an indirect labeling system with end-point measurement was further used, to avoid 
chemical modification of the in-situ synthesized peptides but to use them right after the 
synthesis. 
 
III.1.2. Indirect labeling techniques 
III.1.2.1. Labeling via FLAG/HA antibody epitope tags 
 
A well-established technique in biochemistry used for purification, Western blot analysis and 
many more, is the fusion of an epitope tag to a protein of interest. For example a poly 
histidine sequence (His-tag) can be used for affinity purification due to its metal chelating 
properties. Other epitopes like the FLAG- and HA-tag are frequently used together with their 
specific anti-FLAG and anti-HA antibodies.72 This system can also be implemented on a 
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peptide array. In order to test if proteases are active on the PEPperChipTM arrays, the peptide 
content was adapted with an FLAG-, HA- and HA-related tag respectively, listed in Table 3. 
 Sequence Specific antibody 
FLAG-tag DYKDDDDK 
monoclonal mouse-anti-
FLAG M2 IgG 
HA-tag YPYDVPDYAG monoclonal mouse-anti-HA 
12CA5 IgG HA-related tag QSYDSKDYSD 
Table 3: List of the used tag-sequences with their specific antibodies; different to the FLAG-tag, the HA 
and HA-related sequences can be permutated without losing complete antibody specificity. 
 
 
Figure 17: Schematic workflow of the FLAG/HA-assay system. 
 
As depicted in Figure 17 the basic idea is that the fluorescently labeled anti-FLAG and anti-
HA antibodies will bind only to full-length peptides, where the epitope sequence is complete. 
When the peptide sequence is cleaved by a protease, the antibody recognition will fail and a 
decrease in fluorescence intensity for this peptide spot can be measured compared to the 
buffer control. The in-situ synthesized arrays were used as delivered without further chemical 
modification; the protection groups were cleaved following the corresponding protocols of the 
manufacturer and the array then blocked with a 2% (m/v) PVP-TBS-T solution, to avoid 
nonspecific adsorption of proteases to the polymer surface. PVP as non-proteinogenic 
compound was used because it will not interfere with the enzyme incubation. After 
proteolysis the array was again blocked, this time using Rockland buffer©; as standard 
proteinogenic blocking agent used in the lab, it reduces background fluorescence due to non-
specific binding of antibodies to the polymer surface.  
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Figure 18: Peptide array (17meres) with FLAG-, HA- & HA-related sequences, stained with their specific 
antibodies after protease incubation length (the 10mere epitopes were elongated with a repetitive GS-
sequence); a) buffer control, b) proteinase k, c) trypsin, d) chymotrypsin, e) elastase.  Overall enzyme 
concentration was 5µM, 2h incubation time at 37°C; antibody staining was performed with a 1:1000 dilution out of 
a 10mg/ml stock solution; Read out was performed on the Odyssey scanner for near-infrared dyes (intensity 7). 
 
Figure 18 shows the fluorescence scan after enzyme incubation and antibody staining with 
the corresponding peptide map. For each peptide spot five replicates were printed. For data 
quantification the decrease in fluorescence intensity of the enzyme incubated subarrays was 
compared with the buffer control. To reduce the failure of diverse spot morphologies, the 
average over identical sequence replicates was taken. The intensity variances in the buffer 
control can be explained due to different binding forces between the antibody and its epitope 
when the sequence is slightly substituted with other amino acid residues. 
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Figure 19: Quantification of the fluorescence scan (Figure 12) after 5µM enzyme incubation at 37°C for 2h. 
For analysis the average over 5 identical peptide spots was taken, the box plots show the minimum and maximum 
possible decrease in fluorescence intensity due to proteolytic cleavage including the outliers, proteinase k and 
trypsin were scaled logarithmically for a better overview; Analysis was performed using the PepSlideAnalyzer 
Software; the boxplots show the range between minimum and maximum cleavage efficiency and median value. 
 
As depicted in Figure 19, the best cleavage efficiencies were obtained for the HA-related 
epitope, down to almost zero percent fluorescence intensity due to the various cleavage sites 
in the epitope sequence. Trypsin, cleaving specifically after lysine and arginine residues, 
shows the best results when comparing the HA-tag which does not bear a tryptic cleavage 
site with its cleavable analogues. Chymotrypsin is active against aromatic amino acid side 
chains but shows a lower significance against the HA-epitope, similar to proteinase k with its 
unspecific endo- and exo-proteolytic properties. Elastase showed the lowest cleavage 
activities in this set of proteases. However a low cleavage of the FLAG-epitope was obtained 
only with trypsin and elastase maybe due to its higher content of acidic amino acids in the 
sequence or the orientation relative to the active centers of the enzymes. As illustrated in 
Figure 20, the control frame sequences, although consisting of FLAG- and HA-tags, were not 
cleaved at all. One explanation could be the short peptide length, only 8meres compared to 
the full-length peptide content with its 17-20meres. Therefore it is harder for the enzymes to 
reach the cleavage sites. 
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Figure 20: Quantification of the fluorescence scan (Figure 18) control frame after 5µM enzyme incubation 
at 37°C for 2h. The control sequences were directly synthesized on the polymer without elongation and N-
terminally acetylated.   
 
After those results further experiments using trypsin and endoproteinase asp-N, as two very 
specific proteases, latter cleaving after aspartic acid residues, were done to check for 
reproducibility and to minimize the extent of outliers due to protease specificity. Furthermore, 
the enzyme incubation time was extended to look for maximally possible cleavage efficiency. 
Figure 21 shows the obtained fluorescence scan for two different enzyme concentrations 
after overnight incubation. Besides the FLAG-epitope several HA- and HA-related tags with 
and without tryptic cleavage sites were used. The 10mere epitopes were elongated using a 
repetitive GS-sequence like before and substituted along the full peptide sequence from N- 
to C terminus. The quantification data for trypsin in Figure 22 show that for an overnight 
incubation even for lower enzyme concentration almost the same results can be obtained as 
for higher concentration. The proportionate cleavage of the HA-tag which does not bear a 
tryptic cleavage site can be attributed to chymotryptic contamination of the used trypsin. This 
time, the FLAG-epitope was nicely cleaved. 
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Figure 21: Peptide array (17meres) with various FLAG-, HA- & HA-related sequences as depicted in the 
legend, stained with their specific antibodies after protease incubation; the epitope sequences were 
substituted along the full peptide length (the 10mere epitopes were elongated with a repetitive GS-
sequence). a) 125nM asp-N, b) 62.5nM asp-N, c) 5µM trypsin, d) 2.5µM trypsin, e) buffer control.  Overnight 
incubation at 37°C; antibody staining was performed with a 1:1000 dilution out of a 10mg/ml stock solution; Read 
out was performed on the Odyssey scanner for near-infrared dyes (intensity 7). 
 
 
Figure 22: Quantification of the fluorescence scan (Figure 16) after trypsin incubation overnight at 37°C. 
For analysis the average over identical epitope sequences was taken; for sequences which were completely 
cleaved, no boxplot is shown. Analysis was performed using the PepSlideAnalyzer Software.  
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Figure 23: Quantification of the fluorescence scan (Figure 16) after asp-N incubation overnight at 37°C. 
For analysis the average over identical epitope sequences was taken; for sequences which were completely 
cleaved, no boxplot is shown. Analysis was performed using the PepSlideAnalyzer Software. 
Asp-N as highly specific sequencing protease yields an overall very good cleavage of all 
peptides bearing an aspartic acid side chain. As a next step the concentration dependency of 
trypsin for a fixed enzyme incubation time of two hours was tested, to evaluate the 
achievable sensitivity of this system. An incubation time of two hours was chosen because it 
represents a reasonable duration to address a sufficient cleavage. 
 
Figure 24: Quantification data of the concentration dependency of trypsin after 2h incubation at 37°C 
(fluorescence scan not shown). Concentrations below 0.3µM showed no significant cleavage after incubation 
time; for analysis the average over identical epitope sequences was taken; analysis was performed using the 
PepSlideAnalyzer Software. 
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As depicted in Figure 24, good cleavage efficiencies could be obtained with trypsin 
concentrations down to 0.31µM; all subordinate values were insufficient for the used 
incubation time (data not shown here). Finally a minimum concentration of 1.25µM showed 
the best results with a cleavage below 10% fluorescence intensity. However, also the 
cleavage of the epitope sequence QSYDSADYSD, without any tryptic cleavage site, was 
observed, likely due to chymotryptic contamination, which is caused by the production 
process of the used trypsin. Further the FLAG-epitope in this production batch remained 
uncleaved again which indicates a batch to batch variance.   
In summary, it was shown that proteolytic cleavage of in-situ synthesized peptides on the 
used peptide microarrays is possible in principle. With trypsin and asp-N, as very specific 
proteases, the most promising results could be obtained; only the FLAG sequence showed 
batch to batch variation and no reproducible cleavage. Since the used antibody recognition 
sites represent a complex peptide sequence which would lead to false positive cleavage 
pattern in the further assay system when working with clinical specimen because it cannot be 
distinguished between cleavage of the epitope or the actual peptide sequence below, an 
alternative labeling system has to be found.  
 
III.1.2.2. Using acetyl-lysine as antibody recognition tag 
 
When it comes to antibody epitopes, normally a sequence of at least six amino acid residues 
is needed for specific binding. In 1989, Hebbes et al. produced an antibody which is 
specifically directed against a single modified amino acid residue, the ε-N-acetyl lysine.73 
Since this building block has been introduced as toner particle in the in-situ synthesis at 
PEPperPRINT©, it is possible to check for its suitability as non-cleavable peptide label. 
Therefore, the used peptide contents were adapted with an N-terminal Fmoc-ε-N-acetyl 
lysine. Prior to antibody staining the protection groups were cleaved and the slides blocked 
with TBS-T containing 2% PVP, to avoid non-specific binding. Afterwards the array was first 
incubated with the primary antibody against ε-N-acetyl lysine, followed by the secondary 
goat-anti-rabbit IgG (H+L) DylightTM680 conjugated antibody for the actual staining. The 
antibodies were used in different concentrations to identify the best dilution. A 1:20000 for 
the primary and a 1:5000 dilution for the secondary antibody yielded the best spot intensities, 
as depicted in Figure 25. However the signal to noise ratio turned out to be way too high for a 
proper analysis. Despite of that, further experiments revealed specificity problems of the 
used anti-acetyl lysine antibody. Peptide sequences with basic amino acid residues next to 
the label for example showed no binding of the antibody compared to others. 
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Figure 25: Peptide array (17meres) with N-terminal Ac-Lys-residues, stained with anti-MEY-ac OVA as 
primary and goat-anti-rabbit IgG (H+L) DylightTM680 conjugated as secondary antibody. Antibody staining 
was performed with a 1:20000 (primary) & 1:5000 (secondary) dilution out of a 10mg/ml stock solution, 60min & 
30min respectively; Read out was performed on the Odyssey scanner for near-infrared dyes (intensity 7). 
 
The obtained results lead to the conclusion that this alternative labeling system is not 
compatible with the aimed protease assay. 
 
III.1.2.3. Labeling via biotin-streptavidin system 
 
In order to find a labeling alternative for the established FLAG/HA-system, it had to be taken 
into account that the labeling molecule should be ideally non-proteinogenic and also small in 
size to reduce any possible steric hindrance. In the early 1960´s Chaiet and Wolf found that 
biotin, also called vitamin B7, has a strong binding to a biomolecule named streptavidin, 
isolated from streptamycetes.74 Biotin itself is a small bicyclic compound found as prosthetic 
group for carboxylases and also as histone modifying agent in the cell nucleus.75 One 
streptavidin protein is able to bind four biotin molecules in a very strong and specific way. 
Therefore biotin was chosen as N-terminal labeling reagent which is commercially available 
as activated NHS-ester. For the analysis after protease incubation, a fluorescently labeled 
streptavidin was used. The biotinylation was carried out under standard aqueous buffer 
conditions, using a 2.2mM solution of biotin-X-NHS in PBS-T. Biotin-X-NHS has a six atom 
spacer arm to reduce steric effects. 
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Figure 26: Peptide array (17meres) with various sequences & FLAG/HA control frame (top row & left 
column) labeled with 2.2mM biotin-X-NHS in PBS-T for 2h at room temperature. a) Streptavidin test 
staining & chemical structure of biotin-X-NHS; b) 2nd streptavidin test staining of buffer control (right) and 
1.25µM asp-N (left); c) additional to (b) stained with anti-FLAG-antibody. Enzyme incubation was carried out 
overnight at 37°C; streptavidin staining was performed using a 1:5000 dilution out of a 10mg/ml stock solution; 
antibody staining was performed using a 1:1000 dilution out of a 10mg/ml stock solution; Read out was performed 
on the Odyssey scanner for near-infrared dyes (intensity 7 green channel, intensity 2 red channel). 
 
Figure 26 shows the chemical structure of the used biotin labeling compound together with 
the first streptavidin test staining which indicated a good labeling efficiency and specificity 
(a). Also the low background interference is a plus. Further experiments however showed a 
lack in reproducibility as depicted in (b) where the spots show no specific labeling but the 
peripheral grid together with a worse background to noise ratio. When incubating with asp-N 
no difference in fluorescence intensity could be obtained, therefore a test staining with an 
anti-FLAG antibody was performed, shown in (c), to check for cleavage of the control frame 
peptides which showed a positive result. The obtained reproducibility problems seem to be 
similar to the ones gained with the fluorescence dye labeling. The similarity of both labeling 
systems lies in the in-solution coupling of the labeling compound to their specific functional 
groups of the peptides. To avoid the afterwards chemical modification of the peptides out of 
solution, a biotin toner was developed at the company PEPperPRINT on the basis of a biotin-
OPfp-ester reagent to adapt the standard synthesis process, where the toner particles are 
slightly melted during the synthesis and form a gel-like pillow on top of the spots. It seems to 
be advantageous compared to in-solution reactions because the gel-like state allows 
diffusion of the reactant to the functional groups in the polymer in a very distinct area which 
minimizes cross-reactions in deeper polymer layers and/or unspecific physisorption.71  
34 
 
 
Figure 27: a) Peptide content with N-terminal printed biotin [in-situ synthesis]; b) peptide content N-
terminal labeled with 2.2mM biotin-X-NHS in PBS-T for 2h at room temperature [in-solution labeling];       
c) 125nM asp-N on printing-labeled array; d) 125nM asp-N on in-solution labeled array. Enzyme incubation 
was carried out overnight at 37°C; streptavidin staining was performed using a 1:5000 dilution out of a 10mg/ml 
stock solution; Read out was performed on the Odyssey scanner for near-infrared dyes (intensity 2). 
 
Figure 27 shows the comparison between biotin labeled peptide arrays modified in-situ (a) 
and in-solution (b) with the corresponding proteinase k digestion (c) & (d). Obviously the in-
situ synthesized arrays show no background fluorescence compared to the in-solution 
labeling which indicates a non-specific binding to the surface polymer and/or the peptides in 
the last case, like before when labeling with fluorescent dyes. After incubation with 
proteinase k the in-situ array shows a complete digestion of the peptide content as expected, 
whereas the in-solution array shows insufficient decrease in fluorescence, especially for the 
control frame and the grid of the peptide spots. This inhomogeneous pattern makes a proper 
analysis impossible. Further experiments were therefore based on the in-situ biotin labeled 
peptide arrays. As a next step standard protease incubation with trypsin was performed as 
showed in Figure 28. 
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Figure 28: Quantification data of a standard peptide array after 5µM trypsin and trypsin sequence grade 
incubation at 37°C overnight (fluorescence scan not shown). ; For analysis the average over identical epitope 
sequences was taken; Analysis was performed using the PepSlideAnalyzer Software. 
 
Here again a cleavage of both, peptides with distinct tryptic cleavage site and without, show 
a similar decrease in fluorescence intensity. To check if it is due to chymotryptic or other 
impurities of the used enzyme, trypsin in sequence grade was used. This led to a significant 
improvement, although still a decrease in fluorescence intensity down to around 50% for the 
control peptide was measured. This failure can be partly attributed to the fact that the 
digested spots are compared to a reference spot which is located in a different area on the 
microarray surface. Due to manufacturing purposes, the polymer properties within one array 
and the synthesis efficiency of single spots can slightly vary (leads to outliers). Further while 
incubating with buffers, staining solution etc. there are obviously differences because of 
many parameters like shaking, diffusion, protein repellency etc. that in accumulation can lead 
to the obtained deviations. In addition to trypsin, a protease with a more complex cleavage 
site was chosen to check for the potential of the present array technology. Thrombin, being 
an important part of the blood coagulation cascade, represents such an enzyme. It cleaves 
peptide sequences between arginine and glycine depending on the surrounding residues. As 
depicted in Figure 29, the peptide sequences from natural proteins of the coagulation system 
show the highest decrease in fluorescence intensity compared to the synthetic tripeptides. 
The control peptides show also a decrease due to some outliers (possible reasons discussed 
earlier in this chapter).  
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Figure 29: Quantification data of a standard peptide array after 30µM thrombin incubation at 37°C for 2h 
(fluorescence scan not shown). For analysis the average over identical epitope sequences was taken; Analysis 
was performed using the PepSlideAnalyzer Software. 
 
III.1.2.4. Short summary and conclusion 
 
In the second part of this chapter it has been shown that proteolytic cleavage of peptides on 
in-situ synthesized peptide microarrays is working in principle. Preliminary experiments used 
complex peptide epitopes (FLAG- & HA-tag) and their specific fluorescently labeled 
antibodies for detection. As such complex sequences are not suitable for an enzymatic assay 
system due to the possible false cleavage of the label instead of the actual peptide sequence 
of interest; an alternative label was needed, which does not interfere with the proteolysis. 
Acetyl lysine fulfills this requirement and there are specific antibodies commercially available. 
However the antibody binding is highly dependent on the label surrounding amino acid 
residues, where for example basic rests have an inhibiting influence. Further the high 
background to noise ratio makes an analysis very difficult and not very reliable. Despite of 
the antibody systems, the use of biotin as labeling tag together with its specific binding 
protein streptavidin, showed promising results with trypsin and thrombin as model proteases. 
Anyhow the preliminary proteolytic data show no complete decrease in fluorescence 
intensity, even when high enzyme concentrations and longer incubation times are used. 
There is a gap of at least 20% which could be attributed to the polymer characteristics and 
the loss of a degree of freedom when working on a surface based system instead of solution. 
In regard to optimize the system when working with more challenging proteases and finally 
clinical samples, the next chapter will focus on surface chemistry. 
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III.2. Surface chemistry 
III.2.1. New polymer coating – Dextran 
III.2.1.1. Background 
 
The standard coating of a PEPperChipTM is based on a polyethylene glycol, methyl 
methacrylate copolymer (PEGMA/MMA) on standard glass plates, mainly following the 
protocol from Stadler et al.76 with a film thickness of 13.5nm and a (10/90) PEGMA/MMA 
composition. This polymer film showed good protein repellent properties with a still sufficient 
wettability which is optimized by using small amounts of Tween20 as detergent. However 
when performing protease digestions, this coating seems to have certain limitations 
regarding accessibility especially for challenging enzymes like thrombin or proteases from 
serum samples. To address this problem another type of surface coating was tested on basis 
of polysaccharides which represents a biological hydrogel. Dextran turned out to be the 
coating material of choice because of its similar biocompatibility and protein repellency 
compared to PEG-based polymers. Dextran chains are not branched and remain very 
flexible; therefore the accessibility of peptides for proteases within the matrix should be 
improved.77 Another advantage is the chemical stability and the cheap and easy synthesis 
process, also in regard to upscaling to production scale. Figure 30 illustrates schematically 
the on-chip synthesis of a dextran coating based on the protocol from Luo et al.78  
 
Figure 30: Schematic overview of the coating process using dextran on standard silica glass. 
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In the first step, standard silica glass slides were cleaned and activated by overnight 
incubation in a 1M KOH/iPrOH solution. After washing and curing, the slides were silanized 
with APTES / DCM solution overnight, followed again by a curing step. The resulting amino 
terminated surfaces were then modified using an activated CM-dextran. Finally the dextran 
matrix was amino functionalized to be further used for spotting or in-situ peptide synthesis. 
 
III.2.1.2. Test of dextran coating with spotted peptides 
 
Figure 31 shows the polymer thicknesses after silanization and dextran modification verified 
via ellipsometry. Different concentrations of silane and dextran solutions were tested in order 
to find the optimum polymer composition. 
 
Figure 31: Characterization of silane & dextran layer; left: Variation of thickness of the silane layer with 
change in APTES concentration after overnight incubation on Si(100) wafer; right: Variation of thickness 
of the dextran layer with change in CM-Dextran concentration after overnight incubation on silanized 
Si(100) wafer (0.0025% APTES). 
 
The silanization using APTES showed a linear increase in film thickness. Higher 
concentrations up to 2.5% led to thick multilayers of around 80-90nm which stands for about 
100 layers with regard to its monomer size of 0.89nm.79,80. After the following dextran 
modification, using a 5% dextran solution, a resulting polymer thickness of 13-16nm was 
achieved which indicates a loss of silane layers during dextran incubation and the instability 
of such thick silane films. Therefore, a reduced APTES concentration (0.0025%) was used, 
which led to a stable 4.49nm layer, to test for the variation of thickness of the dextran layer. 
The dextran modification showed a rather asymptotic increase in polymer thickness up to 
around 7nm. A 5% dextran solution gave the best results regarding polymer stability against 
chemicals used in SPPS. Regarding the reproducibility of silanization, a 2.5% APTES 
solution was further used to ensure a proper reaction. Polymer stability was in this case the 
main priority whereas the polymer thickness should not interfere with its biocompatibility.  For 
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the following spotting of N-terminally biotinylated sample peptides, the amino terminated 
polymer surface was functionalized by using a NHS-maleimide linker for the cysteine 
mediated linkage. Table 3 shows the peptide sequences used for this experimental setup. 
Peptides 1 and 2 represent a synthetic thrombin cleavage sequence where the enzyme 
cleaves after proline and arginine. The hexamer sequence was located N-terminally for 
peptide 1 and C-terminally for peptide 2 to check for accessibility of the enzymes. Peptide 3 
represents a natural thrombin cleavable sequence from fibrinogen. All three sample peptides 
also contain cleavage sites for trypsin. 
 Sequence 
Peptide 1 Bio-GSLVPRGSGSGSGSGSKKGC 
Peptide 2 Bio-GKKSGSGSGSGSLVPRGSGC 
Peptide 3 Bio-LSNNAIGPRSFSQNSRHPGC 
Control Bio-GSGSGSGSGSGSGSGSGSGC 
Table 3: Set of spotted peptides. 
 
 
Figure 32: Test staining after peptide spotting (5 replicates); a) dextran coating, b) PEGMA/MMA coating, 
c) dextran coating after chemical stress test. Streptavidin staining was performed using a 1:5000 dilution out 
of a 10mg/ml stock solution; Read out was performed on the Odyssey scanner for near-infrared dyes (intensity 4). 
 
Figure 32 shows the spotted peptide pattern on dextran and PEGMA/MMA polymer after 
streptavidin staining. Compared to PEGMA, the spots on dextran show a slightly extended 
spot morphology which indicates an increased wettability of the coating. The chemical stress 
test of the new dextran films with TFA and piperidine showed no negative influence. As 
depicted in Figures 33 and 34, proteolysis on dextran surfaces show a similar decrease in 
fluorescence intensity with trypsin compared to the standard PEGMA films. With thrombin 
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however an optimization of around 20% could be achieved. As next step a kinetic 
measurement was performed to check for sensitivity, especially for shorter time points. 
Figure 35 shows the trypsin incubation over two hours with four time points measured.  
 
Figure 33: Enzyme digestion of spotted peptide pattern; a) dextran coating, b) PEGMA/MMA coating. 
Enzyme incubation was carried out 2h at 37°C; streptavidin staining was performed using a 1:5000 dilution out of 
a 10mg/ml stock solution; Read out was performed on the Odyssey scanner for near-infrared dyes (intensity 4).  
 
 
Figure 34: Quantification data of spotted peptide array after 5µM enzyme incubation at 37°C for 2h 
(fluorescence scan not shown). For analysis the average over identical replicates was taken; Analysis was 
performed using the PepSlideAnalyzer Software. 
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Proteolysis with thrombin on the other hand showed an overall increase in digestion of about 
20% for peptide 1 and 3, as depicted in Figure 36. Peptide 2 though, having the cleavage 
site C-terminally located, is hardly cleaved by thrombin on both coatings. It has to be taken 
into account that this model system is not representative for every enzyme but at least the 
dextran polymer turned out to be a promising alternative to the PEGMA film. Its synthesis 
process is cheap and does not need excessive volumes of organic solvents compared to the 
PEGMA-based polymers. Further the production can easily be up-scaled. As a next step a 
standard 22 x 21 cm glass plate was coated with dextran and introduced into the in-situ 
peptide synthesis at PEPperPRINT© GmbH. 
 
 
Figure 35: Kinetic measurement of spotted sample peptides using 5µM trypsin as digesting enzyme over 
2h at 37°C on dextran and PEGMA surfaces. 
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Figure 36: Kinetic measurement of spotted sample peptides using 5µM thrombin as digesting enzyme 
over 2h at 37°C on dextran and PEGMA surfaces. 
 
III.2.1.3. Dextran coating in the in-situ synthesis 
 
For testing the new dextran polymer in the in-situ synthesis, the surface coating was 
performed using the optimized conditions discussed in the last chapter (2.5% APTES 
solution & 2.5% CM-Dextran solution). Prior to the actual SPPS, a standard linker (2 β-
alanine + aspartic acid) was printed to set up the synthesis pattern. After the peptide 
synthesis a comparison of the peptide load, quantified via OD-measurement after Fmoc-
cleavage, showed an average peptide load of ~1.46nmol/cm2 for dextran; compared to the 
standard PEGMA/MMA films with about ~0.84nmol/cm2, this about 1.7 fold higher value 
however could be a disadvantage for a protease assay because of the higher amount of 
peptides that have to be digested. This would lead to an increased amount of time or higher 
enzyme concentration needed, compared to the PEGMA/MMA surface. The test staining 
showed a similar spot morphology like using standard PEGMA/MMA-polymers. Figure 37 
shows exemplary an enzymatic digestion with the model proteases proteinase k and trypsin. 
For both proteases an overall decrease in fluorescence intensity of around 30% was yielded. 
In order to compensate the higher peptide load, higher enzyme concentrations as well as a 
longer incubation time were checked. Unfortunately even with a 10 fold higher enzyme 
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concentration and an incubation time of 18 hours, no significantly increase in proteolytic 
digestion could be achieved. 
 
Figure 37: Peptide content with N-terminal printed biotin [in-situ synthesis on dextran film]; a) 5µM 
trypsin, b) 5µM proteinase K; c) Buffer control. Enzyme incubation was carried out for 2h at 37°C; streptavidin 
staining was performed using a 1:5000 dilution out of a 10mg/ml stock solution; Read out was performed on the 
Odyssey scanner for near-infrared dyes (intensity 4). 
 
In summary it could be shown that polysaccharide-based polymers like dextran are a good 
alternative surface coating compared to the standard PEGMA/MMA films used so far in 
terms of easy applicable synthesis process, upscaling to production parameters and low 
costs. Preliminary experiments using standard microscopy glass slides and pre-synthesized 
spotted peptides showed promising results using model proteases. In the next step this new 
dextran synthesis method was transferred to the production scale at PEPperPRINT© GmbH. 
The first batch of in-situ PEPperChipsTM showed an almost 2 fold higher peptide load 
compared to the standard PEGMA/MMA coatings but comparable spot morphologies and 
sufficient fluorescence intensity in the tests, both with antibody and streptavidin staining. 
However preliminary protease experiments showed an insufficient digestion of the peptides 
on the new implemented surface coating, even with 10 fold higher enzyme concentrations 
and elongated incubation times. It has to be taken into account that optimization of the 
dextran polymer is ongoing and the whole surface and peptide synthesis process takes 
around 5 to 6 weeks per batch. Further the transfer of lab to production scale is not fully 
comparable because of the use of pre-synthesized, spotted peptides against the in-situ 
synthesis. Using micro-particle based peptide synthesis (mpSPPS), the surface polymer is 
stressed with chemicals resulting from the coupling procedures, the matrix of the micro-
particles, etc. in every synthesis cycle (~35 to 50 cycles, dependent on the peptide length) 
whereas in lab scale only one mild coupling step is performed.  
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IV. Conclusion 
 
Conclusion 
The aim of the present work was to develop an enzymatic assay system based on 
combinatorically synthesized peptide microarrays, manufactured in close cooperation with 
the company PEPperPRINT© GmbH. This goal was achieved by introducing a specific label 
N-terminally to the peptide sequences which can be stained and read out after protease 
incubation via fluorescence measurement. To check for general applicability the peptide 
arrays were synthesized with N-terminal located antibody tags (FLAG & HA), by using the 
standard micro-particle based peptide synthesis (mpSPPS) without further chemical 
modification. After protease incubation only fully intact, tagged peptide sequences are 
stained with their specific, fluorescently labeled antibodies. The decrease in fluorescence 
intensity represents the enzymatic activity. The results using trypsin and proteinase k as 
model enzymes were promising. To address a broader range of proteases, biotin as non-
proteinogenic label was introduced, after being available as micro-particle based building 
block, which cannot be falsely cleaved, like an antibody tag, but specifically stained by using 
a fluorescently labeled streptavidin. It turned out to be advantageous to stick to the mpSPPS 
method for labeling the peptide content with biotin, to reduce nonspecific binding to the 
polymer surface, like found when performing in-solution labeling experiments.  A direct 
labeling via fluorescent dyes to yield an on-demand measurement approach however was 
not successful; due to the high contamination risk and technical difficulties, fluorescent dyes 
could not be embedded into micro-particles for the in-situ synthesis. With the established 
biotin-streptavidin system and the corresponding model proteases, kinetic data varying 
enzyme concentration as well as incubation time, was obtained. In order to optimize the on-
chip proteolysis, an alternative surface coating based on polysaccharides was prepared. The 
experimental dextran polymer showed promising results in lab scale, using spotted peptides. 
Further the easy synthesis process and up-scaling to production parameters, together with 
the low costs compared to the standard PEGMA/MMA coating, are a major advantage. After 
transferring the new coating procedure to production scale, the resulting peptide load turned 
out to be around 1.7 fold higher than on PEGMA/MMA which seems in consequence to be 
too high for a proper enzymatic digestion on a solid support. Here a decrease in fluorescence 
intensity down to 70% using proteinase k could be obtained which indicates the need of 
optimization.  
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Outlook 
In principle enzymatic activity in a sample of interest can be measured with peptide 
microarrays. The established model system has shown that the protease assay can be 
directly performed on the biotin labeled PEPperCHIPTM arrays without modification. 
To further optimize the assay system several tasks remain. First of all the surface polymer 
has to be modified in a way that a preferably high number of proteases can be addressed in 
terms of accessibility of their cleavage sites. Preliminary experiments with the alternative 
dextran coating yielded a high peptide load, compared to the standard PEGMA/MMA, which 
is not feasible for the targeted assay system. A reduction here should lead to higher 
cleavage efficiencies, plus less need of incubation time and enzyme concentration in the 
sample; together with an optimization of the polymer synthesis, regarding the silanization and 
dextran modification steps, to obtain an optimum film thickness, this will lead probably to a 
more sensitive monitoring. In the present work silanization and the following adding of 
dextran, corresponding to an approximate film thickness of ~100nm after silane and ~15nm 
for the final film, showed promising results in lab scale using spotted peptides. The transfer 
to production scale at PEPperPRINT© GmbH is still an ongoing process and will be pursued 
in the future. Furthermore the overall applicability of the dextran polymer for all experimental 
approaches offered on standard PEGMA/MMA based PEPperCHIP´sTM has to be further 
studied.  
Another task in the future will be to further investigate the possibility of a direct labeling 
approach using fluorescent dyes or other on-demand measurement techniques. In the 
present work the difficulties of specifically labeling in-situ synthesized peptides out from 
solution have been discussed. If it would be possible in the future to embed fluorescent dyes 
into the mpSPPS production process, this would be a major advantage.  
Although there are still some parameter to be further investigated, the established model 
system already shows the general applicability of high density peptide microarrays as tool for 
measuring protease activity. With further optimization, this work paves the way for testing 
clinical samples so that such arrays can help to advance the field of peptide marker 
screenings in the future. 
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V. Material & Methods 
 
V.1. Devices & Measuring parameters 
V.1.1. Ellipsometry 
 
Film thicknesses were measured with an M-44 multiple wavelength ellipsometer (J. A. 
Woollam Co. Inc., Lincoln, NE/USA). Sample alignment was at a nominal incidence angle of 
75° to the surface normal. Polymer layer thicknesses were determined using the appendant 
WVASE software and a single CAUCHY model layer81. Clean Si(100) wafers kept in air are 
usually covered with a 21-25 Å thin SiO2 layer82,83 on which SAMs of organo-silanes can be 
assembled as an anchor group for polymers. The thickness of the polymer coating in such 
multilayered systems was determined by measuring the sample against a UV- or acid-
cleaned reference wafer (silicon bulk + silicon oxide). Assuming homogeneous molecular 
packing (silicon bulk + silicon oxide + organic layer) the CAUCHY model was used to fit the 
thickness of the organic layers. 
 
V.1.2. Fluorescence Scans 
 
Fluorescence scans were performed with the Odyssey Infrared Imager (LI-COR Biosciences, 
Lincoln, NE/USA) or the GenePix 4000B Microarray Scanner (Molecular Devices, Sunnyvale, 
CA/USA) depending on the wavelength of the used fluorescent dye. 
Odyssey Infrared Imager 
The Odyssey Infrared Imager is equipped with two solid state lasers simultaneously 
providing light excitation at 685 and 785 nm. Accordingly the Odyssey was used to scan 
samples stained with the DyLight680 and DyLight800 dyes. Image acquisition was performed 
with the Odyssey Application Software 3.0 (V. 3.0.21). The Odyssey Infrared Imager was 
routinely set to 21 µm resolution and a detector intensity of 4.0 for streptavidin-DL680 stained 
samples and 7.0 for Anti-HA-DL680 stained samples. Quantitative analyses were performed 
with the SICASYS PepSlide Analyzer Software (V. 2.0.9.). 
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GenePix 4000B Microarray Scanner 
The GenePix 4000B Microarray Scanner is a microscopy slide scanner equipped with two 
solid state lasers providing simultaneous light excitation at 532 and 635 nm. Accordingly the 
GenePix was used to scan samples stained with TAMRA, DyLight550 and Benzofurazan 
dyes. Image acquisition was performed with the GenePix Pro 6.0 Acquisition and Analysis 
Software. The scan resolution was set to 5 µm, scan power to 33 % and PMT (photo 
multiplier tube) between 300 and 500, depending on fluorescence intensity in a pre-scan. 
PMT values above 500 lead to interferences due to auto-fluorescence of the glass and 
should be avoided. 
 
V.1.3. Spotting Robot 
 
The peptide arrays were spotted using the BioRobotics Microgrid II spotting robot with a 
single contact spotting tip. Each peptide solution was prepared in filtered PBS-T (pH 7.4, 
0.15 M) and filled in Small Volume 384 Well Plates (Greiner Bio-One GmbH, 
Frickenhausen/Germany). Spotting layout and gal-file export were performed with the TAS 
Application Suite (V. 2.4.0.3). 
 
V.2. Materials 
V.2.1. Chemicals & Solvents 
 
DyLight680-streptavidin (Pierce Protein Research Products), DyLight550-Phosphine and 
SMCC were obtained from Thermo Fisher Scientific (Geel/Belgium). 
Biotin-OPfp was purchased from Iris Biotech GmbH (Marktredwitz/Germany).  
TFA (≥99.9 %), Ac2O (≥99 %), DIPEA (≥99 %), DCM (≥99.9 %), KH2PO4 (≥99 %), Na2HPO4 · 
2 H2O (≥98 %) and DMSO (≥99.5 %) were obtained from Carl Roth (Karlsruhe/Germany). 
TRIS (≥99.9 %) was obtained from Santa Cruz Biotechnology Inc. (Dallas, TX/USA). 
DMF (≥99.8 %) and HCl (37 %) were purchased from VWR International (Radnor, PA/USA). 
ACN (HPLC-grade) was obtained from VWR International S.A.S. (Fontenay-sous-
Bois/France). 
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KOH (p.a.) and DCM (≥98.9 %, anhydrous) were purchased from AppliChem GmbH 
(Darmstadt/Germany). 
PVP (MW= 40,000 g/mol) and KCl (99.5 %) were obtained from Merck KGaA 
(Darmstadt/Germany). HBTU was obtained from Merck Schuchardt OHG 
(Hohenbrunn/Germany). 
HOBt (anhydrous) was obtained from Molekula Ltd. (Dorset/UK). 
All used PEG-derivatives were obtained from Rapp Polymere GmbH (Tübingen/Germany). 
TAMRA-5-Maleimide (≥95 %), TAMRA-5-NHS, TAMRA-5-COOH (≥95 %), Fmoc-β-azido-
Ala-OH (≥98 %), Tween20, EtOH (p.a.), MeOH (p.a.), iPrOH (p.a.), acetone (p.a.), β-
mercaptoethanol (min. 98%), NaCl (≥99 %), 4-chloro-7-nitro-benzofurazan, DMF (anhydrous, 
99.8 %), CDI, APTES (≥98 %), piperidine (99 %), Trizma® base (≥99.9 %), CaCl2 · 2 H2O 
(≥99.9 %), CM-Dextran sodium salt, NHS (98 %) and NH2-Maleimide-Linker (≥95 %) were 
obtained from Sigma-Aldrich GmbH (Steinheim/Germany). All chemicals and solvents were 
used without further purification. 
Syringe filters were purchased from Sartorius Stedim Biotech GmbH (Göttingen/Germany). 
Nitrogen (5.0, P200) was purchased from Guttroff GmbH (Wertheim-
Reichholzheim/Germany). For washing steps and buffers solely Milli-Q-filtered water 
(Millipore Corporation, Merck KGaA, Darmstadt/Germany, resistivity ~ 18.2 MΩcm) was 
used. 
 
V.2.2. Pre-synthesized peptides 
 
All pre-synthesized peptides were purchased from Peps4LifeSciences GmbH 
(Heidelberg/Germany) and used as delivered. 
 
V.2.3. Buffers, Antibodies, Enzymes  
PBS-T 
0.15 M phosphate buffer saline (PBS) containing additional 0.05 % (v/v) Tween20 (PBS-T) 
was freshly prepared before use. 8.00 g NaCl (137.00 mmol), 0.20 g KCl (2.7 mmol), 1.44 g 
Na2HPO4 · 2 H2O (8.1 mmol) and 0.20 g KH2PO4 (1.5 mmol) were solved in water. The 
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solution was adjusted to pH 7.4 with HCl and filled up to 1 L. After filtration 500 µl Tween20 
were added under constant stirring. 
 
TBS-T 
0.20 M TRIS-buffer saline (TBS) containing additional 0.05 % (v/v) Tween20 (TBS-T) and     
25 mM Calcium was freshly prepared before use. 6.00 g Trizma® base (50 mmol), 8.80 g 
NaCl (150 mmol) and 11.60 g CaCl2 · 2 H2O (20 mmol) were solved in water. The solution 
was adjusted to pH 7.4 with HCl and filled up to 1 L. Afterwards 500 µl Tween20 were added 
under constant stirring. 
 
Rockland buffer 
Rockland Blocking Buffer for Fluorescent Western-Blotting (Rockland buffer) was obtained 
from Rockland Immunochemicals Inc. (Gilbertsville, PA/USA) and used as received. 
 
Antibodies 
The monoclonal mouse-anti-HA 12CA5 IgG antibody (Anti-HA) was obtained from Dr. 
Gerhard Moldenhauer (German Cancer Research Centre (DKFZ), Heidelberg/Germany). 
The monoclonal mouse-anti-FLAG M2 IgG antibody (anti-FLAG) was purchased from Sigma-
Aldrich GmbH (Steinheim/Germany). The monoclonal anti-MEY-ac OVA antibody (anti-
acetyl-lysine antibody) was obtained from David Biotech (Technical University Darmstadt 
(TUDa), Darmstadt/Germany). The goat anti-rabbit IgG (H+L) antibody (DylightTM680 
conjugated) was obtained from Thermo Scientific (Germany). Fluorescent labels were 
attached by Jürgen Kretschmer (German Cancer Research Centre (DKFZ), 
Heidelberg/Germany) using commercial labeling kits and the respective protocols which were 
recommended by the manufacturers. Labelling kits for DyLight680 and DyLight800 were 
obtained from Innova Biosciences Ltd. (Cambridge/UK). 
 
Enzymes 
All purchased enzymes were portioned in 50 µl aliquots and stored under -20°C. Trypsin 
(from porcine pancreas, 1 mg tablet, dissolved following the manufacturers protocol), 
thrombin (from bovine plasma, 40-300 NIH), elastase (from porcine pancreas, ≥4 NIH) and 
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chymotrypsin (Type VII, TLCK treated, ≥40 NIH) were obtained from Sigma-Aldrich GmbH 
(Steinheim/Germany). Proteinase k (20 mg/ml solution) was purchased from Genaxxon 
Bioscience GmbH (Ulm/Germany). 
 
V.2.4. Microarray surfaces 
 
For all self-manufactured surfaces in lab scale, standard microscopy glass slides from 
Marienfeld (Lauda-Königshofen/Germany) were used.  
 
V.2.5. Peptide microarrays 
 
All peptide microarrays were purchased from PEPperPRINT GmbH (Heidelberg/Germany). 
Upscaling of the dextran surface coating (see V.3. Methods) and testing was performed 
together with PEPperPRINT GmbH.  
 
V.3. Methods 
V.3.1. Preparation of synthesis surfaces 
 
In the present work standard microscopy glass slides were equipped with a synthesis 
coating. The derivatization of Si(100) wafers was routinely performed in petri dishes (V≈50 
ml). Microscopy glass slides were treated in batches of 5 to 10 slides in standard glass 
washing chambers (V≈ 200 ml) and petri dishes (V≈ 100-200 ml). The 22 x 21 cm2 glass 
slides used in large scale at PEPperPRINT GmbH were coated in a custom-built Teflon 
incubation container (V≈ 1 L). 
 
V.3.1.1. Cleaning & Activation 
 
Glass surfaces were cleaned and activated by overnight treatment with 1M KOH in 2-
propanol. The surfaces were intensively washed with water, rinsed with acetone and dried in 
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a stream of air. After heating to 100°C for 1h the slides were allowed to cool to RT and stored 
under -20°C and inert gas atmosphere till use. 
Si(100) wafers were activated by UV radiation for 1h in air at PEPperPRINT GmbH. UV 
radiation was generated with a 150 W mercury vapor lamp (Heraeus Noblelight GmbH, 
Hanau/Germany, model TQ150, purchased from UV consulting Peschl, Mainz/Germany). 
The surface was put in about 4 cm distance from the lamp. After cooling to RT the wafers 
were directly used for further silanization.  
For lab scale the wafers were activated by overnight incubation in caro acid (50% H2SO4 in 
H2O2). The surfaces were intensively washed with water and dried at 100°C before further 
use. 
 
V.3.1.2. Self-assembly of APTES 
 
A solution of 2.5% APTES (v/v) in anhydrous DCM was prepared and directly added to the 
dry, activated surfaces. The surfaces were left to react overnight. Subsequently, the DCM 
was stepwise replaced with ethanol. The surfaces were washed three times 5 min each with 
ethanol, two times 5 min each with acetone, dried in a stream of air and baked in a pre-
heated oven at 100°C for 2h. After cooling to RT the slides were either used directly for 
dextran coating or stored at -20°C under nitrogen. In some cases rests of precipitated 
colorless powder had to be removed by 15 min ultra-sonication in ethanol.  
 
V.3.1.3. Dextran coating 
 
Dextran films were grafted on the silanized surfaces according to the following protocol: 2.5 g 
CM-Dextran (≈ 50 mg/ml), 1.62 g CDI (10 mmol) and 1.15 g NHS (10 mmol) were mixed in 
50 ml Milli-Q-water. The pH value was adjusted to pH 8.0 with NaOH and then filtered with a 
standard syringe filter (5.00 µm). The filtered solution was then added to the surfaces in a 
petri dish and left to react overnight under constant shaking at RT. Subsequently, the 
surfaces were washed three times 5 min each with Milli-Q-water and two times 5 min each 
with DMF. After rinsing with acetone, the surfaces were blown dry in a stream of air and 
stored under -20°C and nitrogen till further use. 
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For coating of production scale plates at PEPperPRINT© GmbH the reaction was up-scaled 
to the required volume. A piece of silanized Si(100) was added to the reaction as a reference 
to determine the respective film thickness via ellipsometry. 
 
V.3.1.4. Capping of dextran coatings 
 
Dextran surfaces were capped according to following protocol: A freshly prepared solution of 
10 % ESA, 20 % DIPEA and 70 % DMF (v/v) was added to the slides three times 30 min 
each. Subsequently, the surfaces were washed three times 5 min each with DMF, two times 
5 min each with MeOH and 5 min with acetone. After rinsing with acetone the slides were 
blown dry in a stream of air and stored under -20°C and nitrogen till further use. 
 
V.3.1.5. Amino-functionalization of dextran 
 
Dextran coatings were amino-functionalized according to following protocol: 2.43 g CDI     
(15 mmol) was mixed with 50 ml ACN and the solution added to the surfaces. The slides 
were left to react 30 min at RT under constant shaking and then washed once 5 min with 
ACN. 1.26 ml 1,3-diaminopropane (15 mmol, 1.11 g) was mixed with 50 ml ACN and the 
solution added to the surfaces. The slides were left to react 1h at RT under constant shaking. 
Subsequently, the surfaces were washed three time 5 min each with ACN and two times 5 
min each with MeOH. After rinsing with acetone the slides were blown dry in a stream of air 
and stored under -20°C and nitrogen till further use. 
 
V.3.2. Coupling of SMCC, NH2-Mal-Linker & Spotting 
 
A solution of 3 mM SMCC in anhydrous DMF was prepared. Amino-functionalized surfaces 
were placed in a petri dish and covered with 1 ml of the SMCC solution each. After 2h 
incubation the slides were washed three times 5 min each with DMF, two times 5 min each 
with MeOH and 5 min with acetone. After rinsing with acetone the surfaces were dried in a 
stream of air and either used directly for further spotting experiments or stored under -20°C 
and nitrogen till further use.  
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After peptide spotting the slides were left to react for additional 90 min and then rocked for 60 
min in a solution of 5 % β-mercaptoethanol in EtOH (v/v). The slides were then washed three 
times 5 min each with EtOH and 5 min with acetone and afterwards dried in a stream of air. 
 
V.3.3. Micro particle-based peptide synthesis 
 
Micro particles containing Opfp-activated and Fmoc-protected amino acids or Opfp-activated 
biotin were selectively addressed onto the linker-modified surfaces using the laser printer 
technique49. The peptide synthesis on the 22 x 21 cm2 glass slides was commissioned to the 
PEPperPRINT GmbH (Heidelberg/Germany). 
 
V.3.4. N-terminal modification of printed Peptides from Solution 
V.3.4.1. Biotin-Opfp 
 
To couple Biotin-Opfp to the N-termini of printed peptides, a solution of 2.4 mM Biotin-Opfp in 
anhydrous DMF was prepared. The surfaces were placed in a petri dish and covered with     
1 ml of the coupling solution and left to react overnight at RT. The slides were washed three 
times 5 min each with DMF, two times 5 min each with MeOH and 5 min with acetone. After 
rinsing with acetone the slides were blown dry in a stream of air and stored under -20°C and 
nitrogen till further use. 
 
V.3.4.2. TAMRA-COOH, Fmoc-TAMRA-Lys-OH & Fmoc-β-N3-Ala-OH 
 
To couple TAMRA-COOH, Fmoc-TAMRA-Lys-OH & Fmoc-β-N3-Ala-OH to the N-termini of 
printed peptides, a solution of 1 mM TAMRA-COOH, 10 mM Fmoc-TAMRA-Lys-O or            
10 mM Fmoc-β-N3-Ala-OH in anhydrous DMF was prepared. The same volume of a solution 
of 10 mM HOBt, 10 mM HBTU and 10 mM DIPEA was added. The surfaces were placed in a 
petri dish and covered with 1 ml of the coupling solution and left to react overnight at RT. The 
slides were washed three times 5 min each with DMF, two times 5 min each with MeOH and 
5 min with acetone. After rinsing with acetone the slides were blown dry in a stream of air 
and stored under -20°C and nitrogen till further use. 
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V.3.4.3. TAMRA-NHS 
 
To couple TAMRA-NHS to the N-termini of printed peptides, a solution of 20µM TAMRA-NHS 
in PBS-T was prepared. The surfaces were placed in a petri dish and covered with 1 ml of 
the labeling solution and left to react for 2h at RT. The slides were washed three times 5 min 
each with PBS-T, two times 5 min each with Milli-Q-water, blown dry in a stream of air and 
stored under -20°C in an inert gas atmosphere till further use. 
 
V.3.4.4. Atto680-Mal, Dylight800-Mal & TAMRA-Mal 
 
To couple Atto680-Mal, Dylight800-Mal & TAMRA-Mal, a solution of 0.3µM Atto680-Mal 
0.3µM Dylight800-Mal or 0.7µM TAMRA-Mal in PBS-T was prepared. The surfaces were 
placed in a petri dish and covered with 1 ml of the labeling solution and left to react for 2h at 
RT. The slides were washed three times 5 min each with PBS-T, two times 5 min each with 
Milli-Q-water, blown dry in a stream of air and stored under -20°C in an inert gas atmosphere 
till further use. 
 
V.3.4.5. FlAsH-EDT2 
 
To couple FlAsH-EDT2, a solution of 7.5mM FlAsH-EDT2 in PBS-T with 0.1M DTT was 
prepared. The surfaces were placed in a petri dish and covered with 1 ml of the labeling 
solution and left to react for 2h at RT. The slides were washed three times 5 min each with 
PBS-T, two times 5 min each with Milli-Q-water, blown dry in a stream of air and stored 
under -20°C in an inert gas atmosphere till further use. 
 
V.3.4.6. Dylight550-Phosphine & TAMRA-PEG(3)-N3 
 
To couple Dylight550-Phosphine & TAMRA-PEG(3)-N3, a solution of 10µM Dylight550-
Phosphine & TAMRA-PEG(3)-N3 in PBS-T was prepared. The surfaces were placed in a 
petri dish and covered with 1 ml of the labeling solution and left to react for 4h at 37°C. The 
slides were washed three times 5 min each with PBS-T, two times 5 min each with Milli-Q-
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water, blown dry in a stream of air and stored under -20°C in an inert gas atmosphere till 
further use. 
 
V.3.5. Blocking 
V.3.5.1. PVP-Blocking prior to enzyme incubation 
 
To block the surfaces prior to enzyme incubation, a solution of 2% (m/v) PVP (MW=40000) in 
TBS-T was prepared. The surfaces were placed in a 16 well incubation chamber, the target 
wells covered with 200µl of the blocking solution and left to react for 1h at RT. 
 
V.3.5.2. Rockland-blocking 
 
To block the surfaces prior to antibody or streptavidin staining, Rockland buffer was used 
directly without dilution. The surfaces were placed in a 16 well incubation chamber, the target 
wells covered with 200µl of the blocking solution and left to react for 1h at RT. 
 
V.3.6. Enzyme incubation 
 
For protease incubation, a solution of 5µM of the target enzyme in 0.2% (m/v) PVP 
(MW=40000) TBS-T was prepared. The surfaces were placed in a 16 well incubation 
chamber, the target wells covered with 200µl of the protease solution and left to react for 2h 
at 37°C. The slides were washed three times 5 min each with TBS-T and used further for 
staining. 
 
V.3.7. Antibody staining 
V.3.7.1. Anti-FLAG/anti-HA antibodies 
 
For staining of the FLAG/HA antibody tags, a dilution of 1:1000 out of a stock solution (anti-
HA: 95µg/ml in PBS + 0.02% NaN3 + 10% Rockland buffer; anti-FLAG: 0.21mg/ml in PBS + 
0.02% NaN3 + 10% Rockland buffer) of a monoclonal mouse-anti-HA 12CA5 IgG antibody 
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(Anti-HA) or monoclonal mouse-anti-FLAG M2 IgG antibody (anti-FLAG) respectively in TBS-
T with 10% (v/v) Rockland buffer was prepared. The surfaces were placed in a 16 well 
incubation chamber, the target wells covered with 200µl of the staining solution and left to 
react for 1h at RT. The slides were washed three times 5 min each with PBS-T, two times 5 
min each with Milli-Q-water, blown dry in a stream of air and stored under 4°C in an inert gas 
atmosphere. 
 
V.3.7.2. Anti-Ac-Lys-staining  
 
For staining of the acetylated lysine residues, a dilution of 1:20000 out of a stock solution 
(primary: 2.08mg/ml in PBS + 0.02% NaN3; secondary: 1mg/ml in PBS + 1% BSA + 0.02% 
NaN3) of a monoclonal anti-MEY-ac OVA antibody (anti-acetyl-lysine antibody, primary) and 
a dilution of 1:5000 of a goat anti-rabbit IgG (H+L) antibody (DylightTM680 conjugated, 
secondary) in 0.2% PVP (m/v) TBS-T respectively was prepared. Prior to antibody staining 
the surfaces were blocked with 2% (m/v) PVP (see V.3.5.1.). The surfaces were placed in a 
16 well incubation chamber, the target wells covered with 200µl of the staining solution and 
left to react for 30min for the primary and 1h for the secondary antibody at RT. The slides 
were washed three times 5 min each with PBS-T, two times 5 min each with Milli-Q-water, 
blown dry in a stream of air and stored under 4°C in an inert gas atmosphere. 
 
V.3.8. Streptavidin staining 
 
For staining of biotinylated surfaces, a dilution of 1:5000 out of a stock solution (1mg/ml in 
PBS + 0.02% NaN3) of DylightTM680 conjugated streptavidin in TBS-T with 10% (v/v) 
Rockland buffer was prepared. The surfaces were placed in a 16 well incubation chamber, 
the target wells covered with 200µl of the staining solution and left to react for 1h at RT. The 
slides were washed three times 5 min each with PBS-T, two times 5 min each with Milli-Q-
water, blown dry in a stream of air and stored under 4°C in an inert gas atmosphere. 
 
V.3.9. Spotting of pre-synthesized peptides using the BioRobotics Microgrid II spotting robot 
 
For all spotting experiments pre-synthesized peptides purchased from Peps4LifeSciences 
GmbH were used as delivered and diluted in Milli-Q-water to yield a 1mM stock solution, 
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stored at -20°C till further use. For spotting a final concentration of 50µM diluted in PBS-T 
was used. After spotting the slides were left to react for another 90min at RT, blocked with a 
10% (v/v) mercaptoethanol in ethanol solution for 1h at RT and washed three times 5 min 
each with ethanol, two times 5 min each with acetone and blown dry in a stream of air and 
stored under -20°C in an inert gas atmosphere till further use. 
 
V.3.10. Micro-particle based peptide synthesis 
 
Micro particles containing the Opfp-activated Biotin or Opfp-activated and Fmoc-protected 
amino acids were selectively addressed onto the dextran modified surfaces using the laser 
printer technique.49 The peptide synthesis on the 22 x 21cm2 glass plates was commissioned 
to the company PEPperPRINT© GmbH (Heidelberg/Germany). Then the solid supports were 
transferred into a pre-heated oven and allowed to react at 90°C for 90 min under nitrogen 
atmosphere. After cooling to RT, unreacted amino groups were capped with 10% (v/v) Ac2O, 
20% (v/v) DIPEA and 70% (v/v) DMF; Glass slides/plates were rocked in an excess of this 
mixture for 30 min. Subsequently, the surfaces were washed three times 5 min each with 
DMF and 5 min with acetone. The surfaces were either stored at 4°C under argon 
atmosphere or directly deprotected for the next coupling cycle. To cleave the Fmoc 
protecting group, the glass slides/plates were rocked in a solution of 50% (v/v) piperidine in 
DMF for 30 min. Subsequently the surfaces were washed three times 5 min each with DMF, 
two times 5 min each with MeOH and 5 min with acetone and then blown dry in a stream of 
compressed air. Then the next particle deposition was performed. 
 
V.4. Analytical techniques 
V.4.1. UV/Vis Photospectrometry 
 
In standard SPPS following the Fmoc-protection strategy, before each coupling cycle the N-
terminal Fmoc-protecting group has to be cleaved prior to attachment of the next building 
block. The piperidine dibenzofulvene adduct (PDFA) resulting from the reaction as 
intermediate product has an absorption maximum at 301nm (Figure 38). The concentration 
of the PDFA adduct in the deblocking solution can be measured using UV/Vis 
Photospectrometry comparing its absorption with a blanc solution. Based on that, the amino 
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group loading and therefore the peptide load in nmol/cm2 on the surface can be calculated 
following the Lambert-Beer´s law (see equation 1).84,85,86 
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Figure 38: Schematic overview of Fmoc-cleavage and PDFA formation. 
 
𝑃𝑃𝑃𝑃𝑃𝑃𝑃 𝑙𝑙𝑙𝑃 =  𝑛
𝐴
=  𝐸 ∙ 𝑉
𝜀 ∙ 𝑃 ∙ 𝐴
 
Equation 1: Peptide load calculated by Fmoc-cleavage; n= amount of substance in mole; A= surface area 
covered with deprotection solution; E= extinction; V= applied volume of deprotection solution; ε= extinction 
coefficient; d= path length of cuvette. 
 
All absorption measurements were routinely performed by PEPperPRINT© GmbH as part of 
the quality management system. 
 
V.4.2. Spectroscopic ellipsometry 
 
In order to characterize different surface properties like film thickness, surface roughness, 
and optical constants etc. ellipsometry can be used because of its sensitivity to the change in 
the optical response of incident radiation that interacts with the investigated material. 
Typically the change in polarization due to reflection, absorption, scattering or transmission is 
measured. Spectroscopic ellipsometry allows film thickness measurements down to single 
atomic layers in a contact-free and non-destructive manner, also working under liquids.82,87 
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To yield maximum sensitivity, the angle of incidence and the wavelength of the incident 
beam are controlled. This procedure is referred to as variable angle spectroscopic 
ellipsometry (VASE). 
Ellipsometry uses a beam of linearly polarized light, where the s- and p-components are 
analyzed. s refers to the light vector component perpendicular to the plane of incidence and 
p to the one parallel. Coming from the light source, both components are in phase with each 
other. When interacting with a material, the s- and p-components are phase-shifted. The s-
component is normally reflected, whereas the p-component is mostly refracted into the 
optically denser medium. This leads to an ellipse-like projection of the electrical field vector 
perpendicular to the plane of the propagated direction of the beam.87 Ellipsometry uses not 
absolute, but the ratio of reflected and incident light intensities, shown in equation 2. 
𝑅𝑥 = 𝐼𝑟𝑥𝐼0𝑥 = |𝑟𝑥|2 
Equation 2: Ratio of reflected and incident light intensity R. I=intensity, r= Fresnel reflection coefficient 
(indices: r= reflected, x= s- or p-polarized, 0= incident).  
 
The Fresnel coefficient is also linked to the components of the electric field vector E and the 
refractive indices η as shown in equation 3. 
 
Figure 39: Reflection and refraction of a light beam at the interphase between two media. 
 
𝑟𝑠 = 𝐸𝑟𝑠𝐸0𝑠 = 𝜂1 cos(𝜗1) − 𝜂2cos (𝜗2)𝜂1 cos(𝜗1) + 𝜂2cos (𝜗2) 
𝑟𝑝 = 𝐸𝑟𝑝𝐸0𝑝 = 𝜂2 cos(𝜗1) − 𝜂1cos (𝜗2)𝜂2 cos(𝜗1) + 𝜂1cos (𝜗2) 
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Equation 3: Fresnel refraction coefficients. r= Fresnel reflection coefficient, E= component of the electric field 
vector, η= refractive index, ϑ= incident angle (indices: r= reflected, 0= incident, s/p= s-/p-polarized, 1= Medium A, 
2= Medium B). 
According to Snell law the ratio of the sines of the incident angles is equivalent to the 
opposite ratio of the refractive indices (see equation 4). sin (𝜗1)sin (𝜗2) = 𝜂2𝜂1 
Equation 4: Snell law of refraction.  
 
In the fundamental equation of ellipsometry, the Fresnel coefficients are related to the 
amplitude factor ψ and the phase factor Δ (see equation 5). Measuring those two factors is 
directly related to material properties and can be used to calculate the thickness of individual 
layers in multilayered systems. 
𝑟𝑝
𝑟𝑠
= tan (𝜓)𝑃𝑖∆ 
Equation 5: Fundamental equation of ellipsometry. Ψ= amplitude factor, i= imaginary unit, Δ= phase factor. 
 
In real systems however an algebraic solution is complicated because of additional 
parameters like surface roughness and multilayers, where the reflected light is a 
superposition of all beams reflected from the different interphases (see Figure 40). To solve 
this problem a regression analysis is required to identify those unknown parameters such as 
film thickness or optical constants. 
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Figure 40: Reflection and refraction in a three-layer system. The incident beam is reflected and refracted at 
the interphase between layer A and B. The refracted beam in layer B is again reflected and refracted at the 
interphase between layer B and C. 
 
In the present work ellipsometry has been used to determine the thickness of organic layers 
on a solid support. The Fresnel coefficients for such three-layer systems as depicted in 
Figure 35 are given in equation 6 (Layer A= Air, B= organic layer, C= solid support). 
𝑟𝑥 = 𝑟𝑥12 + 𝑟𝑥23 ∙  𝑃−𝑖2𝜑1 + 𝑟𝑥12 + 𝑟𝑥23 ∙  𝑃−𝑖2𝜑 
𝜑 = 2𝜋 �𝑃
𝜆
� 𝜂2cos (𝜗2) 
Equation 6: Fresnel reflection coefficients for a three-layer system. d= thickness of layer B with the refractive 
index η2, λ= wavelength (indices: 1= layer A, 2= layer B, 3= layer C; x= s-/p-polarized). 
 
Out of the comparison of the phase shift of a wave which is reflected at the interphase of 
layer A & B and B & C respectively, the thickness of layer B can be obtained. For 
determination of the film thickness of organic layers on a reflecting substrate, the refractive 
index as parameter is needed. Frequently the refractive indices of a material is unknown; in 
this case the Cauchy model can be used to parametrize the values (see equation 7).81 To 
increase the accuracy, measurements are usually performed at multiple wavelengths. 
𝜂(𝜆) = 𝜂0 + 𝑌𝜆2 
Equation 7: Cauchy parametrization of the refractive index. Y= Cauchy parameter. 
62 
 
For further information regarding the theoretical background as well as the technical 
application and setup reference is made to the literature.82,83,87 
 
V.4.3. Fluorescence spectroscopy 
 
Luminescence is the emission of light from any substance and occurs from electronically 
excited states. The general term can be divided into two categories, fluorescence and 
phosphorescence, depending on the nature of the excited state. If the electron in the excited 
state is of opposite spin to the one in the ground state, this state is called singlet state. The 
return of the excited electron back to the ground state is spin-allowed and is rapidly done by 
emission of a photon. Typically this process lasts around 10ns. If the electron in the excited 
state has the same spin orientation as the one in the ground state, this is called triplet state. 
The return to the ground state is in this case spin-forbidden which leads to elongated 
emission rates from milliseconds to seconds as phosphorescence. In general fluorescence 
data are presented as emission spectra, where the fluorescence intensity versus wavelength 
or wavenumbers is plotted. To illustrate the ongoing processes between absorption and 
emission, a Jablonski diagram is commonly used (see Figure 41). 
 
Figure 41: General form of a Jablonski diagram. S0= singlet ground state, S1,2= first/second excited singlet 
state, T1= first excited triplet state, hν= energy of a photon. 
 
 At each of the electronic energy levels the fluorophore can exist in a number of vibrational 
levels, donated by 0, 1, 2 etc. For the influences of different parameters like quenching, 
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energy transfer or solvent interactions, as well as the overall theoretical background 
reference is made to literature.88  
In the present work fluorescence intensity measurements of peptide microarrays were 
performed using common microarray scanning devices; depending on the experimental 
approach different organic fluorophores were used, emitting at 532/680 or 800nm.  
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VII. Appendix 
 
VII.1. Abbreviations 
 
% (m/v)   mass per volume fraction 
% (v/v)    volume fraction 
Ac2O    acetic anhydride 
APTES   (3-Aminopropyl)triethoxysilane 
asp-N    endoproteinase asp-N from Pseudomonas fragi mutant strain 
Biotin-X-NHS 6-[[5-[(3aS,4S,6aR)-hexhydro-2-oxo-1H-thieno[3,4-d]imidazol-4-
yl]-1-oxopentyl]amino]-2,5-dioxo-1-pyrrolidinyl-ester-hexanoic 
acid 
Biotin-Opfp Biotin-pentafluorophenylester 
CDI 1,1′-Carbonyldiimidazole 
CM-Dextran Carboxymethyl-dextran sodium salt 
DCC N,N′-Dicyclohexylcarbodiimide 
DCM dichloromethane 
DIPEA N,N-diisopropylethylamine 
DMF N,N-Dimethylformamide 
DMSO dimethyl sulfoxide 
DTT threo-1,4-Dimercapto-2,3-butanediol 
e.g. [latin] exempli gratia, for example 
et al. [latin] et alii, and others 
EtOH ethanol 
ESA acetic anhydride 
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FlAsH-EDT2 Fluorescein arsenical helix binder, 4',5'-Bis(1,3,2-dithioarsolan-
2-yl)fluorescein 
Fmoc 9-fluorenylmethoxycarbonyl (protecting group) 
GFP green fluorescent protein 
H hour(s) 
HA Human influenza hemagglutinin 
HBTU 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate 
HOBt 1-hydroxybenzotriazol 
MeCN acetonitrile 
MeOH methanol 
Min minute(s) 
MMA methylmethacrylate 
mpSPPS micro particle-based solid phase peptide synthesis 
MW molecular weight 
NHS 1-Hydroxy-2,5-pyrrolidinedione 
NIH National Institute of Health standard, one "NIH" unit is 
equivalent to 1.1 to 1.3 IU (international unit) of thrombin 
Opfp orthopentafluorophenyl moiety 
PBS-T phosphate buffer saline with additional Tween20 
PDFA piperidinedibenzofulvene adduct 
PEG poly(ethylene glycol) 
PEGMA poly(ethylene glycol) methacrylate 
PMT photomultiplier tube 
iPrOH 2-propanol 
PVP polyvinylpyrrolidone 
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RT room temperature (here 23 °C) 
SMCC succinimidyl-trans-4-(N-maleimidylmethyl)cyclohexane-1-
carboxylate 
SN2 nucleophilic substitution 
TAMRA 5(6)-carboxytetramethyl rhodamine 
TBS-T TRIS buffer saline with additional Tween20 
TFA trifluoroaceticacid 
TRIS Triisopropylsilane 
Tween20 polyoxyethylensorbitan monolaurate (surfactant) 
UV/Vis ultra-violet/visible 
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VII.2. Amino acid codes 
 
Ala A alanine 
Arg R arginine 
Asn N asparagine 
Asp D aspartic acid 
Cys C cysteine 
Gln Q glutamine 
Glu E glutamic acid 
Gly G glycine 
His H histidine 
Ile I isoleucine 
Leu L leucine 
Lys K lysine 
Met M methionine 
Phe F phenylalanine 
Pro P proline 
Ser S serine 
Thr T threonine 
Trp W tryptophan 
Tyr Y tyrosine 
Val V valine 
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